id,conversation_id,created_at,date,time,timezone,user_id,username,name,place,tweet,language,mentions,urls,photos,replies_count,retweets_count,likes_count,hashtags,cashtags,link,retweet,quote_url,video,thumbnail,near,geo,source,user_rt_id,user_rt,retweet_id,reply_to,retweet_date,translate,trans_src,trans_dest
1211343281814212608,1211343281814212608,2019-12-29 23:18:38 IST,2019-12-29,23:18:38,+0530,1493298541,stig_brodersen,Stig T. Brodersen,,"In today's episode, @PrestonPysh, @harirama, @Greenbackd and I discuss the intrinsic value of Biogen, GrafTech, Allstate, and i3 Verticals  Please let us know what you think!   https://t.co/piUrnPH6S4  #TIP $EAF $BIIB $ALL $IIIV  https://t.co/kmqj6ARjd6",en,"[{'screen_name': 'prestonpysh', 'name': 'preston pysh', 'id': '538399586'}, {'screen_name': 'harirama', 'name': 'hari ramachandra', 'id': '14983892'}, {'screen_name': 'greenbackd', 'name': 'tobias carlisle', 'id': '20119344'}]",['https://www.theinvestorspodcast.com/episodes/tip275-mastermind-discussion-4th-q-2019/'],['https://pbs.twimg.com/media/EM-OSMZXYAED54X.jpg'],5,6,56,['tip'],"['eaf', 'biib', 'all', 'iiiv']",https://twitter.com/stig_brodersen/status/1211343281814212608,False,,1,https://pbs.twimg.com/media/EM-OSMZXYAED54X.jpg,,,,,,,[],,,,
1210369779162320896,1210368878964092928,2019-12-27 06:50:17 IST,2019-12-27,06:50:17,+0530,61342056,optionshawk,Joe Kunkle,,Biogen $BIIB buyers active in the afternoon for 1000 January 2021 $450 OTM calls near $17.30,en,[],[],[],0,5,10,[],['biib'],https://twitter.com/OptionsHawk/status/1210369779162320896,False,,0,,,,,,,,[],,,,
1208201768934334464,1208201768934334464,2019-12-21 07:15:23 IST,2019-12-21,07:15:23,+0530,254761995,lonschneidermd,"Lon S. Schneider, MD",,"If you accept @biogen $BIIB unsupported assertions from its EMERGE trial - a really big if - then at best, maybe, aducanumab yields a 16-wk marginal delay in progression vs placebo. And per @jasonkarlawish wld lead to disabling disability to be paid later.",en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'jasonkarlawish', 'name': 'jason karlawish', 'id': '218609170'}]",[],[],3,11,28,[],['biib'],https://twitter.com/LonSchneiderMD/status/1208201768934334464,False,https://twitter.com/jasonkarlawish/status/1207988684609478656,0,,,,,,,,[],,,,
1207777981738954753,1207777981738954753,2019-12-20 03:11:24 IST,2019-12-20,03:11:24,+0530,59485976,psk2329,PSK2329 - JHC,,Biogen authorizes program to repurchase up to $5.0 billion of common stock $BIIB,en,[],[],[],2,5,14,[],['biib'],https://twitter.com/psk2329/status/1207777981738954753,False,,0,,,,,,,,[],,,,
1207773805155946509,1207773805155946509,2019-12-20 02:54:49 IST,2019-12-20,02:54:49,+0530,801116888,cfromhertz,Christian Fromhertz,,$BIIB *BIOGEN RISES 0.8% AFTER ANNOUNCING NEW $5 BLN BUYBACK PROGRAM,in,[],[],[],1,0,11,[],['biib'],https://twitter.com/cfromhertz/status/1207773805155946509,False,,0,,,,,,,,[],,,,
1205583870013239297,1205486581647319041,2019-12-14 01:52:47 IST,2019-12-14,01:52:47,+0530,1180872634449481728,albertoespay,Alberto J Espay,,"@Tuite002 @CurePSP For precision medicine in neurology, this dogma must die: a disease defined by the proteins it aggregates. If we insist that pathology = etiology, we will continue our string of failures. #parkinsons #Alzheimer #BIIB @Roche @ProthenaCorp @biogen @MichaelJFoxOrg @NIHDirector",en,"[{'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}, {'screen_name': 'prothenacorp', 'name': 'prothena corporation', 'id': '1009925912'}, {'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'michaeljfoxorg', 'name': 'michaeljfox.org', 'id': '68784803'}, {'screen_name': 'nihdirector', 'name': 'francis s. collins', 'id': '124237063'}]",[],[],1,2,8,"['parkinsons', 'alzheimer', 'biib']",[],https://twitter.com/AlbertoEspay/status/1205583870013239297,False,,0,,,,,,,,"[{'screen_name': 'Tuite002', 'name': 'Paul Tuite', 'id': '222999592'}, {'screen_name': 'CurePSP', 'name': 'CurePSP', 'id': '28383203'}]",,,,
1203513896033632262,1203513896033632262,2019-12-08 08:47:27 IST,2019-12-08,08:47:27,+0530,254761995,lonschneidermd,"Lon S. Schneider, MD",,"For this #aducanumab @biogen #BIIB #CTAD2019 @CTADconference #ENDALZ media event, and to fracture a bit of history, post Lexington/Concord, at Bunker Hill, we saved our powder and didn't fire until we saw the whites of their eyes -- with great effect.",en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'ctadconference', 'name': 'ctad', 'id': '852545521499635712'}]",[],[],0,0,8,"['aducanumab', 'biib', 'ctad2019', 'endalz']",[],https://twitter.com/LonSchneiderMD/status/1203513896033632262,False,https://twitter.com/jasonkarlawish/status/1203018809159741440,0,,,,,,,,[],,,,
1202990417316171777,1202990417316171777,2019-12-06 22:07:20 IST,2019-12-06,22:07:20,+0530,243215442,mmarchioneap,Marilynn Marchione,,"""we aren‚Äôt going to approve drugs that aren‚Äôt effective,‚Äù #FDA official is quoted as saying. More reading of tea leaves after Biogen's #Alzheimers data at #CTAD2019 $BIIB $ESALY",en,[],[],[],0,6,8,"['fda', 'alzheimers', 'ctad2019']","['biib', 'esaly']",https://twitter.com/MMarchioneAP/status/1202990417316171777,False,https://twitter.com/FayCortez/status/1202976050298445824,0,,,,,,,,[],,,,
1202651688563335169,1202651688563335169,2019-12-05 23:41:21 IST,2019-12-05,23:41:21,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Detailed data on Biogen's resurrected Alzheimer‚Äôs drug raise more questions than answers  https://t.co/77FYIXThyk via @rebeccadrobbins @matthewherper $BIIB,en,"[{'screen_name': 'rebeccadrobbins', 'name': 'rebecca robbins', 'id': '368158573'}, {'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['https://www.statnews.com/2019/12/05/detailed-data-on-biogens-resurrected-alzheimers-drug-raise-more-questions-than-answers/'],[],1,11,15,[],['biib'],https://twitter.com/adamfeuerstein/status/1202651688563335169,False,,0,,,,,,,,[],,,,
1202648432873287680,1202648432873287680,2019-12-05 23:28:25 IST,2019-12-05,23:28:25,+0530,19717430,zbiotech,zach,,"*BIOGEN'S ALZHEIMER‚ÄôS DATA 'NOT THAT IMPRESSIVE,' MIZUHO SAYS  awaiting the uber alz bull take from porges at LR  $BIIB",en,[],[],[],1,1,11,[],['biib'],https://twitter.com/zbiotech/status/1202648432873287680,False,,0,,,,,,,,[],,,,
1202627737267195905,1202627737267195905,2019-12-05 22:06:10 IST,2019-12-05,22:06:10,+0530,103917090,bosbizrowan,Rowan Walrath,,"So far, here's the @biogen aducanumab tl;dr: the drug appears to make a difference in amyloid plaque levels, but shows marginal effect in cognition, memory, etc.  $BIIB  https://t.co/VVkuaD6IJb",en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],"['https://pbs.twimg.com/media/ELCXjQVXsAEtycz.jpg', 'https://pbs.twimg.com/media/ELCXjQdXYAARjt_.jpg', 'https://pbs.twimg.com/media/ELCXjQWXsAIziXc.jpg']",1,3,9,[],['biib'],https://twitter.com/BosBizRowan/status/1202627737267195905,False,,1,https://pbs.twimg.com/media/ELCXjQVXsAEtycz.jpg,,,,,,,[],,,,
1202620515413721090,1202620515413721090,2019-12-05 21:37:29 IST,2019-12-05,21:37:29,+0530,1024475988166500352,vgenomics,Vivid Genomics,,Biogen‚Äôs presentation at #CTAD2019 just starting. This is a hopeful time in the field of #Alzheimer‚Äôs drug development. #ENDALZ $BIIB  https://t.co/tEqLwVqRcK,en,[],[],['https://pbs.twimg.com/media/ELCQ-x5U4AA8geh.jpg'],2,1,5,"['ctad2019', 'alzheimer', 'endalz']",['biib'],https://twitter.com/VGenomics/status/1202620515413721090,False,,1,https://pbs.twimg.com/media/ELCQ-x5U4AA8geh.jpg,,,,,,,[],,,,
1202588690918326273,1202588690918326273,2019-12-05 19:31:01 IST,2019-12-05,19:31:01,+0530,90807052,wallstsai,$AI ‚Ñ¢Ô∏è,,"Why do the director sell shares just 2 days before the crucial data release for the company ?  $BIIB Brian S Posner, Director of #Biogen has sold $308,429 worth of stock on 12/3",en,[],[],[],3,1,7,['biogen'],['biib'],https://twitter.com/WallStSai/status/1202588690918326273,False,,0,,,,,,,,[],,,,
1202386735646167040,1202386735646167040,2019-12-05 06:08:31 IST,2019-12-05,06:08:31,+0530,588507814,scripmandy,Mandy Jackson,,"Weather tomorrow morning for $BIIB aducanumab data at #CTAD19 will be a little chilly by San Diego standards, but at least it‚Äôs supposed to stop raining. Any guesses on the climate in the Indigo ballroom during Biogen‚Äôs hour-long presentation? ü•∂üòÉüßêü§î",en,[],[],[],2,3,7,['ctad19'],['biib'],https://twitter.com/ScripMandy/status/1202386735646167040,False,https://twitter.com/EmojiWeatherCA/status/1202383082667626496,0,,,,,,,,[],,,,
1202362893133635587,1202362893133635587,2019-12-05 04:33:47 IST,2019-12-05,04:33:47,+0530,326315947,optionsaction,Options Action,,Do you bet on Biogen here? @Michael_Khouw says investors are getting bearish. He shares the details. $BIIB  https://t.co/rhoCSMGrXe,en,"[{'screen_name': 'michael_khouw', 'name': 'michael c. khouw', 'id': '306850457'}]",[],[],4,8,29,[],['biib'],https://twitter.com/OptionsAction/status/1202362893133635587,False,,1,https://pbs.twimg.com/media/EK-mrLVWwAAtJ_l.jpg,,,,,,,[],,,,
1202361161829814272,1202361161829814272,2019-12-05 04:26:54 IST,2019-12-05,04:26:54,+0530,16732770,cnbcfastmoney,CNBC's Fast Money,,It's a market-moving moment for Biogen as it prepares to release details on its Alzheimer's drug. @PeteNajarian breaks down what this could mean for shares. $BIIB  https://t.co/ozyxjEI6Qq,en,"[{'screen_name': 'petenajarian', 'name': 'pete najarian', 'id': '14292717'}]",[],[],0,6,17,[],['biib'],https://twitter.com/CNBCFastMoney/status/1202361161829814272,False,,1,https://pbs.twimg.com/media/EK-lGePXkAARIxN.jpg,,,,,,,[],,,,
1202357024664817667,1202357024664817667,2019-12-05 04:10:28 IST,2019-12-05,04:10:28,+0530,90807052,wallstsai,$AI ‚Ñ¢Ô∏è,,$BIIB Biogen to host conference call  Management discusses the Phase 3 top-line results for Aducanumab on a conference call to be held on December 5,en,[],[],[],0,4,11,[],['biib'],https://twitter.com/WallStSai/status/1202357024664817667,False,,0,,,,,,,,[],,,,
1202186014116261888,1202186014116261888,2019-12-04 16:50:55 IST,2019-12-04,16:50:55,+0530,102754598,johncendpts,John Carroll,,"Added Yee note $BIIB: an ""unprecedented call for FDA to approve based on the data and it would be political pressure that forces the hand"" Biogen comes under renewed fire as a leading Alzheimer's expert raises serious questions about the aducanumab data  https://t.co/RF8u2dpJpg",en,[],['https://endpts.com/biogen-case-comes-under-renewed-fire-as-a-leading-expert-in-the-alzheimers-field-raises-some-serious-questions-about-the-aducanumab-data/'],[],0,5,12,[],['biib'],https://twitter.com/JohnCendpts/status/1202186014116261888,False,,0,,,,,,,,[],,,,
1201664176051171329,1201664176051171329,2019-12-03 06:17:20 IST,2019-12-03,06:17:20,+0530,26368450,pearlf,Pearl Freier,,"This is an excellent interview &amp; discussion with Biogen's Chief Medical Officer and EVP Research &amp; Development Al Sandrock, moderated by @matthewherper on 11/21 #statsummit . Interesting questions from knowledgeable members of the audience too.  https://t.co/7LZ3o9ExuO $BIIB",en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['http://bit.ly/2Yhy3rm'],[],0,4,7,['statsummit'],['biib'],https://twitter.com/PearlF/status/1201664176051171329,False,,0,,,,,,,,[],,,,
1201597752943239169,1201597752943239169,2019-12-03 01:53:23 IST,2019-12-03,01:53:23,+0530,25360971,powerlunch,Power Lunch,,"Baird analyst Brian Skorney getting bearish on @biogen. He says don't buy the ""hype"" around the company's Alzheimer's drug. $BIIB  https://t.co/XfX7ZAe3QC",en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],[],1,2,11,[],['biib'],https://twitter.com/PowerLunch/status/1201597752943239169,False,,1,https://pbs.twimg.com/media/EKzuyN9X0AEu8yw.jpg,,,,,,,[],,,,
1201516563528060934,1201516563528060934,2019-12-02 20:30:46 IST,2019-12-02,20:30:46,+0530,102754598,johncendpts,John Carroll,,"Analyst Brian Skorney goes grizzly on Biogen‚Äôs Alzheimer‚Äôs ‚Äòhype,‚Äô ‚Äòfearmongering‚Äô and ‚Äòstatistical malpractice‚Äô $BIIB -2.4%  https://t.co/i0DOjmKFYG",en,[],['https://endpts.com/analyst-brian-skorney-goes-grizzly-on-biogens-alzheimers-hype-fearmongering-and-statistical-malpractice/'],[],0,2,10,[],['biib'],https://twitter.com/JohnCendpts/status/1201516563528060934,False,,0,,,,,,,,[],,,,
1201448474639765505,1201448474639765505,2019-12-02 16:00:12 IST,2019-12-02,16:00:12,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Twin notes from Baird‚Äôs @BrianSkorney this morning, d/g‚Äôing $BIIB to a sell and a very skeptical preview of this week‚Äôs aducanumab data presentation. He is the bookend to Biogen bull Geoff Porges.  https://t.co/1z7z1uAQ89",en,"[{'screen_name': 'brianskorney', 'name': 'brian skorney', 'id': '285598594'}]",[],"['https://pbs.twimg.com/media/EKxmzT1WkAA9C_q.jpg', 'https://pbs.twimg.com/media/EKxm02vWsAAdCan.jpg']",2,7,35,[],['biib'],https://twitter.com/adamfeuerstein/status/1201448474639765505,False,,1,https://pbs.twimg.com/media/EKxmzT1WkAA9C_q.jpg,,,,,,,[],,,,
1201404784420380672,1201404784420380672,2019-12-02 13:06:36 IST,2019-12-02,13:06:36,+0530,254761995,lonschneidermd,"Lon S. Schneider, MD",,"I hope people read this before $BIIB @biogen ‚Äòs Dec 5 #aducanumab presentation at #ctad19 @CTADconference   Too bad it‚Äôs behind a @SpringerNature pay wall. It‚Äôs a short piece, someone might get creative and set it free.",en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'ctadconference', 'name': 'ctad', 'id': '852545521499635712'}, {'screen_name': 'springernature', 'name': 'springer nature', 'id': '253588542'}]",[],[],2,4,12,"['aducanumab', 'ctad19']",['biib'],https://twitter.com/LonSchneiderMD/status/1201404784420380672,False,https://twitter.com/ProfRobHoward/status/1200478259911241728,0,,,,,,,,[],,,,
1199101927247757314,1199101927247757314,2019-11-26 04:35:52 IST,2019-11-26,04:35:52,+0530,28571999,bespokeinvest,Bespoke,,"Check out the crazy lines and angles of Biogen's $BIIB 50-day moving average, which normally smooths things out.  Pretty wild.  https://t.co/b3jr3bMeVr",en,[],[],['https://pbs.twimg.com/media/EKQQ2PEWsAAxqR6.png'],0,6,8,[],['biib'],https://twitter.com/bespokeinvest/status/1199101927247757314,False,,1,https://pbs.twimg.com/media/EKQQ2PEWsAAxqR6.png,,,,,,,[],,,,
1198974875639197697,1198974875639197697,2019-11-25 20:11:00 IST,2019-11-25,20:11:00,+0530,26368450,pearlf,Pearl Freier,,"Biogen posted a job opening last week for Senior Director, Global Value and Access, Alzheimer's: ""will lead the launch development of Biogen's Alzheimer's Disease product, potentially the first biologic therapy in Alzheimer‚Äôs Disease""  https://t.co/aIdYTCzaVH $BIIB",en,[],['http://bit.ly/37CM6fa'],[],1,11,15,[],['biib'],https://twitter.com/PearlF/status/1198974875639197697,False,,0,,,,,,,,[],,,,
1197839152152223744,1197839152152223744,2019-11-22 16:58:03 IST,2019-11-22,16:58:03,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Biogen sent us a statement last night after this story was published, now included. Everything else stands.   Biogen‚Äôs top scientist nearly dares FDA not to approve Alzheimer‚Äôs drug  https://t.co/XvwgutcvXj $BIIB",en,[],['https://www.statnews.com/2019/11/21/biogen-al-sandrock-alzheimers/'],[],3,18,33,[],['biib'],https://twitter.com/adamfeuerstein/status/1197839152152223744,False,,0,,,,,,,,[],,,,
1197644962185273344,1197644962185273344,2019-11-22 04:06:24 IST,2019-11-22,04:06:24,+0530,993581474,nedpagliarulo,Ned Pagliarulo,,"If FDA approves aducanumab, running a placebo-controlled study will be difficult, says $BIIB's Al Sandrock in response to question from @matthewherper if Biogen should do second trial.   #STATSummit",en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",[],[],5,8,14,['statsummit'],['biib'],https://twitter.com/NedPagliarulo/status/1197644962185273344,False,,0,,,,,,,,[],,,,
1193863286359543809,1193863286359543809,2019-11-11 17:39:23 IST,2019-11-11,17:39:23,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,LR $BIIB Our 20 Reasons Why Aducanumab Is Likely to Get Approved ‚Ä¢ Bottom Line: Biogen‚Äôs aducanumab (cont)  https://t.co/b181CUlPbz,en,[],['http://tl.gd/n_1sr2eos'],[],2,5,8,[],['biib'],https://twitter.com/_B_I_O_T_E_C_H_/status/1193863286359543809,False,,0,,,,,,,,[],,,,
1192845683964993540,1192845683964993540,2019-11-08 22:15:47 IST,2019-11-08,22:15:47,+0530,13171622,pharmalot,pharmalot,,"Former Biogen sales rep, who says she was fired for complaining about off-label marketing, is awarded $6 million..  https://t.co/I39ajl1oVY #pharma $BIIB #retaliation",en,[],['https://www.statnews.com/pharmalot/2019/11/08/biogen-off-label-marketing-retaliation/'],[],0,4,8,"['pharma', 'retaliation']",['biib'],https://twitter.com/pharmalot/status/1192845683964993540,False,,0,,,,,,,,[],,,,
1189521581288165377,1189521581288165377,2019-10-30 18:06:59 IST,2019-10-30,18:06:59,+0530,758386485846544384,realwillmeade,Will Meade,,$BIIB Biogen Boom up $10 pre mkt,ht,[],[],[],1,3,26,[],['biib'],https://twitter.com/realwillmeade/status/1189521581288165377,False,https://twitter.com/realwillmeade/status/1188821063297314820,0,,,,,,,,[],,,,
1188994985250693120,1188994985250693120,2019-10-29 07:14:29 IST,2019-10-29,07:14:29,+0530,1545630956,ionisdisrupts,Art,,"#TransformedByYes @ionispharma Michael Noon, a 42-year-old man with #SMA type 3, says his life has improved dramatically since he started taking @biogen‚Äôs #Spinraza (nusinersen). Read more about his story here:  https://t.co/0lpm9MBBxe #fds #Biotechnology #goboldly $ions $biib",en,"[{'screen_name': 'ionispharma', 'name': 'ionis pharma', 'id': '4448337313'}, {'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",['http://bit.ly/spinraza-changed-my-life'],[],0,1,9,"['transformedbyyes', 'sma', 'spinraza', 'fds', 'biotechnology', 'goboldly']","['ions', 'biib']",https://twitter.com/IonisDisrupts/status/1188994985250693120,False,,0,,,,,,,,[],,,,
1188614121287290880,1188614121287290880,2019-10-28 06:01:04 IST,2019-10-28,06:01:04,+0530,563084750,traderscom,Traders Community,,Biggest $SPX $DJIA #NASDAQ100  Stock Winners a Last Week* #Tesla $TSLA Biogen $BIIB Algin Technology $ALGN Lam Research $LRCX O Reilly Auto $ORLY Buying or taking profit?  https://t.co/2khG7kKGEh  https://t.co/qILLL10hdk,en,[],['https://traderscommunity.com/index.php/market-talk/1791-market-weekly-october-27-november-2-2019'],['https://pbs.twimg.com/media/EH7OPkpX4AA1FWs.png'],0,3,5,"['nasdaq100', 'tesla']","['spx', 'djia', 'tsla', 'biib', 'algn', 'lrcx', 'orly']",https://twitter.com/TradersCom/status/1188614121287290880,False,,1,https://pbs.twimg.com/media/EH7OPkpX4AA1FWs.png,,,,,,,[],,,,
1188089647416709120,1188089647416709120,2019-10-26 19:17:00 IST,2019-10-26,19:17:00,+0530,857693619406467072,gualestrit,Gualestrit,,Ganancias en la √∫ltima semana  üî∫Biogen $BIIB +30.9% üî∫Tesla $TSLA +27.7% üî∫Pinduoduo $PDD +22.4% üî∫Vipshop $VIPS +21.6% üî∫Seattle Genetics $SGEN +17.4%  üîªInfosys $INFY  -13.0% üîªADS $ADS       -15.2% üîªHasbro $HAS  -21.3% üîªTwitter $TWTR -22.3% üîªNokia $NOK    -27.3%,es,[],[],[],0,10,36,[],"['biib', 'tsla', 'pdd', 'vips', 'sgen', 'infy', 'ads', 'has', 'twtr', 'nok']",https://twitter.com/gualestrit/status/1188089647416709120,False,,0,,,,,,,,[],,,,
1187034553954648065,1187034553954648065,2019-10-23 21:24:26 IST,2019-10-23,21:24:26,+0530,758386485846544384,realwillmeade,Will Meade,,Whale options bets are right on direction of the stock 75% of the time but sometimes they‚Äôre off on timing.  Remember big Biogen calls in early Oct that expired last week 2 days later $BIIB pops 40%. Point is always go back and look at trades that didn‚Äôt work and u may find gold.,en,[],[],[],2,7,56,[],['biib'],https://twitter.com/realwillmeade/status/1187034553954648065,False,,0,,,,,,,,[],,,,
1187024411662135296,1187024411662135296,2019-10-23 20:44:08 IST,2019-10-23,20:44:08,+0530,102094857,adamfeuerstein,Adam Feuerstein,,7 burning questions now that Biogen $BIIB  has resurrected its ‚Äòfailed‚Äô Alzheimer‚Äôs drug  https://t.co/InRDLy5dt1 via @sxbegle,en,"[{'screen_name': 'sxbegle', 'name': 'sharon begley', 'id': '346605991'}]",['https://www.statnews.com/2019/10/23/7-burning-questions-biogen-alzheimers-drug/'],[],0,3,16,[],['biib'],https://twitter.com/adamfeuerstein/status/1187024411662135296,False,,0,,,,,,,,[],,,,
1187004171226173441,1187004171226173441,2019-10-23 19:23:42 IST,2019-10-23,19:23:42,+0530,404422077,squawkcnbc,Squawk Box,,Biogen CEO $BIIB joined us this morning to discuss the Alzheimer's drug the company is submitting to the FDA for approval:  https://t.co/4Fje12pzr1,en,[],[],[],2,7,15,[],['biib'],https://twitter.com/SquawkCNBC/status/1187004171226173441,False,,1,https://pbs.twimg.com/media/EHkV_2OWwAE52JR.jpg,,,,,,,[],,,,
1186972290417856512,1186972290417856512,2019-10-23 17:17:01 IST,2019-10-23,17:17:01,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Experts parse Biogen‚Äôs $BIIB Alzheimer‚Äôs data: Does the treatment work, or is it a mirage?  https://t.co/PEgfeVrVjj More reporting from STAT's @sxbegle and @damiangarde",en,"[{'screen_name': 'sxbegle', 'name': 'sharon begley', 'id': '346605991'}, {'screen_name': 'damiangarde', 'name': 'damian garde', 'id': '529704495'}]",['https://www.statnews.com/2019/10/23/experts-parse-biogens-alzheimers-data-does-the-treatment-work-or-is-it-a-mirage/'],[],3,3,21,[],['biib'],https://twitter.com/adamfeuerstein/status/1186972290417856512,False,,0,,,,,,,,[],,,,
1186744592378613762,1186744592378613762,2019-10-23 02:12:14 IST,2019-10-23,02:12:14,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Alzheimer‚Äôs patients in Biogen $BIIB  trial, jolted by revival of drug, press for access once again  https://t.co/hEv59ebcl1 This is the exceptional story of the Alzheimer's patients and their families whipsawed by today's aducanumab revival. By @DrewQJoseph",en,"[{'screen_name': 'drewqjoseph', 'name': 'andrew joseph', 'id': '359568042'}]",['https://www.statnews.com/2019/10/22/alzheimers-patients-in-biogen-trial-jolted-by-revival-of-drug-press-for-access-once-again/'],[],3,4,12,[],['biib'],https://twitter.com/adamfeuerstein/status/1186744592378613762,False,,0,,,,,,,,[],,,,
1186732769491275776,1186732769491275776,2019-10-23 01:25:15 IST,2019-10-23,01:25:15,+0530,19717430,zbiotech,zach,,"i don't say it often, but props to RJ  *BIOGEN ALZ DRUG HAS 0% CHANCE OF WINNING APPROVAL:RAYMOND JAMES  $BIIB",en,[],[],[],9,6,112,[],['biib'],https://twitter.com/zbiotech/status/1186732769491275776,False,,0,,,,,,,,[],,,,
1186719126598885376,1186719126598885376,2019-10-23 00:31:02 IST,2019-10-23,00:31:02,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Investors are deeply skeptical of Biogen‚Äôs $BIIB Alzheimer‚Äôs claims. They still think it could win approval  https://t.co/oKYGoKtebo My take after speaking to nearly a dozen buyside investors. Plus, one incredible three-card monte gif via @HoganAlex  https://t.co/LifeAffwdd",en,"[{'screen_name': 'hoganalex', 'name': 'alex hogan', 'id': '296572811'}]",['https://www.statnews.com/2019/10/22/investors-are-deeply-skeptical-of-biogens-alzheimers-claims-they-still-think-it-could-win-approval/'],['https://pbs.twimg.com/tweet_video_thumb/EHgSvfzW4AIXh2B.jpg'],1,13,32,[],['biib'],https://twitter.com/adamfeuerstein/status/1186719126598885376,False,,1,https://pbs.twimg.com/tweet_video_thumb/EHgSvfzW4AIXh2B.jpg,,,,,,,[],,,,
1186671229626998791,1186671229626998791,2019-10-22 21:20:43 IST,2019-10-22,21:20:43,+0530,106498703,squawkstreet,Squawk on the Street,,Biogen soaring on news that it is seeking FDA approval for its Alzheimer's drug - our @megtirrell discusses!  @CNBC $BIIB  https://t.co/F7UXzvsyFK,en,"[{'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}, {'screen_name': 'cnbc', 'name': 'cnbc', 'id': '20402945'}]",[],[],1,3,11,[],['biib'],https://twitter.com/SquawkStreet/status/1186671229626998791,False,,1,https://pbs.twimg.com/amplify_video_thumb/1186670911568711685/img/lfCWra4sNrmWlITV.jpg,,,,,,,[],,,,
1186666166758060032,1186666166758060032,2019-10-22 21:00:36 IST,2019-10-22,21:00:36,+0530,106498703,squawkstreet,Squawk on the Street,,Biogen - the story of the morning!  @jimcramer: Biogen's Alzheimer's treatment would be 'the biggest drug ever'  @CNBC @carlquintanilla @davidfaber $BIIB  https://t.co/IeQE1c9QHp,en,"[{'screen_name': 'jimcramer', 'name': 'jim cramer', 'id': '14216123'}, {'screen_name': 'cnbc', 'name': 'cnbc', 'id': '20402945'}, {'screen_name': 'carlquintanilla', 'name': 'carl quintanilla', 'id': '114782468'}, {'screen_name': 'davidfaber', 'name': 'david faber', 'id': '140912249'}]",[],[],5,6,14,[],['biib'],https://twitter.com/SquawkStreet/status/1186666166758060032,False,,1,https://pbs.twimg.com/amplify_video_thumb/1186665802860244992/img/v5JPYEZbAuB6a3iN.jpg,,,,,,,[],,,,
1186662641172959232,1186662641172959232,2019-10-22 20:46:35 IST,2019-10-22,20:46:35,+0530,44438256,matthewherper,Matthew Herper,,More updates to this morning's Biogen story. I think this is it. $BIIB  https://t.co/X1vcKwOy6L,en,[],['https://www.statnews.com/2019/10/22/biogen-to-submit-aducanumab/'],[],2,18,35,[],['biib'],https://twitter.com/matthewherper/status/1186662641172959232,False,,0,,,,,,,,[],,,,
1186659935981113344,1186659935981113344,2019-10-22 20:35:50 IST,2019-10-22,20:35:50,+0530,19717430,zbiotech,zach,,"LR porges on $BIIB -  'We expect Biogen‚Äôs stock to rally strongly today, and should trade in the ~$400 range given partial credit for the value of aducanumab (full value of aducanumab probably prices the stock at $485-525).'  easy there big fella",en,[],[],[],3,2,26,[],['biib'],https://twitter.com/zbiotech/status/1186659935981113344,False,,0,,,,,,,,[],,,,
1186651459510788097,1186651459510788097,2019-10-22 20:02:09 IST,2019-10-22,20:02:09,+0530,758386485846544384,realwillmeade,Will Meade,,Someone just purchased 442 $BIIB 10/25 $300 calls for $4.60 looking for more upside in Biogen,en,[],[],[],4,0,24,[],['biib'],https://twitter.com/realwillmeade/status/1186651459510788097,False,,0,,,,,,,,[],,,,
1186645032994033664,1186645032994033664,2019-10-22 19:36:37 IST,2019-10-22,19:36:37,+0530,102754598,johncendpts,John Carroll,,"OK, I'm done with my last revision -- UPDATED: In a stunning turnaround, Biogen says that aducanumab does work for Alzheimer's ‚Äî but data mining incites controversy and questions $BIIB +gazilllions  https://t.co/f6sugDbxS1",en,[],['https://endpts.com/in-a-stunning-turnaround-biogen-says-that-aducanumab-does-work-for-alzheimers-and-theyre-prepping-a-pitch-to-the-fda/'],[],0,6,5,[],['biib'],https://twitter.com/JohnCendpts/status/1186645032994033664,False,,0,,,,,,,,[],,,,
1186640529183969282,1186640529183969282,2019-10-22 19:18:43 IST,2019-10-22,19:18:43,+0530,342568440,bolsalargoplazo,Bolsa a Largo Plazo,,"Vendo toda mi posici√≥n en Biogen $BIIB. +38% en 6 meses, ojal√° salieran m√°s as√≠... La compr√© porque ten√≠a un potencial de +40%. Una vez alcanzado, ya que no es una acci√≥n para conservar para siempre, la vendo.",es,[],[],[],3,0,19,[],['biib'],https://twitter.com/BolsaLargoPlazo/status/1186640529183969282,False,,0,,,,,,,,[],,,,
1186640421109272578,1186640421109272578,2019-10-22 19:18:17 IST,2019-10-22,19:18:17,+0530,322226692,pekalalaw,Beverly A. Pekala,,"""Old people live too long and this is a risk for the global economy. We must do something, urgently.""--Christine Lagarde. Have a nice day. #LogansRun  #TuesdayThoughts  #Pensions #investments  #Biogen $BIIB  https://t.co/X6EAC3qW6n",en,[],['https://mronline.org/2018/10/09/the-christine-lagarde-memo/'],[],6,6,8,"['logansrun', 'tuesdaythoughts', 'pensions', 'investments', 'biogen']",['biib'],https://twitter.com/PekalaLaw/status/1186640421109272578,False,,0,,,,,,,,[],,,,
1186629159587590146,1186629159587590146,2019-10-22 18:33:32 IST,2019-10-22,18:33:32,+0530,183367527,etfedgecnbc,CNBC's ETF Edge,,The Biotech ETF getting a boost in the premarket after Biogen announced plans to file for FDA approval of its Alzheimer‚Äôs treatment following promising clinical results $IBB $BIIB  https://t.co/eh6Oxq6gdu,en,[],[],['https://pbs.twimg.com/media/EHfA7jOXUAEsblZ.jpg'],0,3,12,[],"['ibb', 'biib']",https://twitter.com/ETFEdgeCNBC/status/1186629159587590146,False,,1,https://pbs.twimg.com/media/EHfA7jOXUAEsblZ.jpg,,,,,,,[],,,,
1186628843156758535,1186628843156758535,2019-10-22 18:32:17 IST,2019-10-22,18:32:17,+0530,1278852289,tradingnation,Trading Nation,,Check out shares of Biogen skyrocketing after the drugmaker announced plans to file for FDA approval of its Alzheimer‚Äôs treatment following promising clinical results $BIIB  https://t.co/gePMEW3a1w,en,[],[],['https://pbs.twimg.com/media/EHfApJlWwAAhn4P.jpg'],0,25,63,[],['biib'],https://twitter.com/TradingNation/status/1186628843156758535,False,,1,https://pbs.twimg.com/media/EHfApJlWwAAhn4P.jpg,,,,,,,[],,,,
1186623022431657984,1186623022431657984,2019-10-22 18:09:09 IST,2019-10-22,18:09:09,+0530,758386485846544384,realwillmeade,Will Meade,,Biogen $BIIB the greatest call in history @unemon1,en,"[{'screen_name': 'unemon1', 'name': 'unemon', 'id': '1105089212'}]",[],[],3,0,12,[],['biib'],https://twitter.com/realwillmeade/status/1186623022431657984,False,https://twitter.com/bespokeinvest/status/1186620806664724480,0,,,,,,,,[],,,,
1186621090895843328,1186621090895843328,2019-10-22 18:01:29 IST,2019-10-22,18:01:29,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Éê„Ç§„Ç™„Ç∏„Çß„É≥Ê±∫ÁÆó Biogen (NASDAQ:BIIB) Q3 EPS(Non-GAAP) $9.17 ‰∫àÊÉ≥Ôºã$0.90 Â£≤‰∏ä $3.6B (+5.0% Y/Y) ‰∫àÊÉ≥Ôºã$60M  https://t.co/eXyMj8QOoC  „Ç¢„É´„ÉÑ„Éè„Ç§„Éû„ÉºÁóÖÊ≤ªÁôÇËñ¨ÂÄôË£ú„Ç¢„Éá„É•„Ç´„Éå„Éû„ÉñÊâøË™ç„Å´Âêë„Åë„ÅüÂãï„Åç„ÅßÊôÇÈñìÂ§ñÊ†™‰æ°+36%  https://t.co/GYj5ITapAG  „Ç®„Éº„Ç∂„Ç§„Å®ÊèêÊê∫„Åó„Å¶„Åü„ÇÑ„Å§Ôºü  https://t.co/bU5mVoDf72  https://t.co/d7WdkCHO0V,ja,[],"['http://investors.biogen.com/static-files/40565136-b61f-4473-9e58-9be769bbac6c', 'https://www.reuters.com/article/us-biogen-alzheimers/biogen-to-seek-u-s-approval-for-alzheimers-drug-shares-jump-21-idUSKBN1X116D', 'https://www.nikkei.com/article/DGXMZO42751620R20C19A3TJC000/']",['https://pbs.twimg.com/media/EHe5jE1VUAEpMVm.jpg'],0,26,72,[],[],https://twitter.com/KessanMan/status/1186621090895843328,False,,1,https://pbs.twimg.com/media/EHe5jE1VUAEpMVm.jpg,,,,,,,[],,,,
1186620806664724480,1186620806664724480,2019-10-22 18:00:21 IST,2019-10-22,18:00:21,+0530,28571999,bespokeinvest,Bespoke,,Biogen $BIIB is set to gap up somewhere between 35-45% this morning.  No stock above $200/share has gapped up 30%+ on earnings since at least 2001 when our Earnings Explorer database begins.   https://t.co/e8LECQTizl,en,[],['https://www.bespokepremium.com/interactive/tools'],[],5,15,44,[],['biib'],https://twitter.com/bespokeinvest/status/1186620806664724480,False,,0,,,,,,,,[],,,,
1186619755156910080,1186619755156910080,2019-10-22 17:56:10 IST,2019-10-22,17:56:10,+0530,2334614718,openoutcrier,Open Outcrier,,"$BIIB (+36.0% pre) Biogen to seek US approval for Alzheimer‚Äôs drug, sending shares soaring - CNBC   https://t.co/a2Fm1ee2Q6",en,[],['http://ooc.bz/l/43217'],[],0,1,5,[],['biib'],https://twitter.com/OpenOutcrier/status/1186619755156910080,False,,0,,,,,,,,[],,,,
1186611616797941760,1186611616797941760,2019-10-22 17:23:50 IST,2019-10-22,17:23:50,+0530,758386485846544384,realwillmeade,Will Meade,,$BIIB Biogen up $40 now or 41% wow,ht,[],[],[],4,1,11,[],['biib'],https://twitter.com/realwillmeade/status/1186611616797941760,False,,0,,,,,,,,[],,,,
1186610586496458758,1186610586496458758,2019-10-22 17:19:44 IST,2019-10-22,17:19:44,+0530,103917090,bosbizrowan,Rowan Walrath,,".@VertexPharma: Yay, we've got monumental drug news that no one expected (five months before the PDUFA date)! @Biogen: Hold my drink.  $BIIB $VRTX",en,"[{'screen_name': 'vertexpharma', 'name': 'vertex pharmaceuticals', 'id': '17542775'}, {'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],[],1,0,15,[],"['biib', 'vrtx']",https://twitter.com/BosBizRowan/status/1186610586496458758,False,,0,,,,,,,,[],,,,
1186606592709595136,1186606592709595136,2019-10-22 17:03:52 IST,2019-10-22,17:03:52,+0530,84402174,street_insider,Streetinsider.com,,Wow! .. Biogen $BIIB now +40%.  RBC calls news 'somewhat astonishing' and sees shares back to low-$300s  https://t.co/9KkR3i7Z8e,en,[],['https://www.streetinsider.com/Corporate+News/Biogen+%28BIIB%29+Says+it+Plans+Regulatory+Filing+for+Aducanumab+in+Alzheimers+Disease+After+Consulting+with+FDA/16031143.html'],[],0,3,9,[],['biib'],https://twitter.com/Street_Insider/status/1186606592709595136,False,,0,,,,,,,,[],,,,
1186605895918260229,1186605895918260229,2019-10-22 17:01:06 IST,2019-10-22,17:01:06,+0530,758386485846544384,realwillmeade,Will Meade,,$BIIB up 35% pre mkt gap fill coming you were warned Biogen,en,[],[],[],3,6,45,[],['biib'],https://twitter.com/realwillmeade/status/1186605895918260229,False,https://twitter.com/realwillmeade/status/1131257454652792833,0,,,,,,,,[],,,,
1186605720873115648,1186597465119703040,2019-10-22 17:00:24 IST,2019-10-22,17:00:24,+0530,3142088601,bertrandbio,Bertrand Delsuc,,üá∫üá∏Biogen $BIIB +34% üá∏üá™Bioarctic $BIOAB +44.5%‚Äº üá∏üá™Alzinova $ALZI +23% (not even in clinics) üá©üá™Vivoryon/ex-Probiodrug $VVY +11%,und,[],[],[],1,2,3,[],"['biib', 'bioab', 'alzi', 'vvy']",https://twitter.com/BertrandBio/status/1186605720873115648,False,,0,,,,,,,,[],,,,
1186601600023965697,1186601600023965697,2019-10-22 16:44:02 IST,2019-10-22,16:44:02,+0530,758386485846544384,realwillmeade,Will Meade,,Wow Biogen $BIIB up 36% pre market @unemon1,ht,"[{'screen_name': 'unemon1', 'name': 'unemon', 'id': '1105089212'}]",[],[],1,0,12,[],['biib'],https://twitter.com/realwillmeade/status/1186601600023965697,False,,0,,,,,,,,[],,,,
1186599435985457152,1186599435985457152,2019-10-22 16:35:26 IST,2019-10-22,16:35:26,+0530,102754598,johncendpts,John Carroll,,"Shiver me timbers -- In a stunning turnaround, Biogen says that aducanumab does work for Alzheimer's ‚Äî and they're prepping a pitch to the FDA $BIIB   https://t.co/f6sugDbxS1",en,[],['https://endpts.com/in-a-stunning-turnaround-biogen-says-that-aducanumab-does-work-for-alzheimers-and-theyre-prepping-a-pitch-to-the-fda/'],[],2,10,31,[],['biib'],https://twitter.com/JohnCendpts/status/1186599435985457152,False,,0,,,,,,,,[],,,,
1186597943161380871,1186597943161380871,2019-10-22 16:29:30 IST,2019-10-22,16:29:30,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"In shocking reversal, Biogen $BIIB to submit experimental Alzheimer‚Äôs drug for approval  https://t.co/ydMxdVNyvh via @matthewherper",en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['https://www.statnews.com/2019/10/22/biogen-to-submit-aducanumab/'],[],3,35,61,[],['biib'],https://twitter.com/adamfeuerstein/status/1186597943161380871,False,,0,,,,,,,,[],,,,
1186596603630620678,1186596603630620678,2019-10-22 16:24:10 IST,2019-10-22,16:24:10,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,$BIIB BIOGEN SHARES UP 35% !!!  PREMARKET AFTER CO PLANS REGULATORY FILING FOR ADUCANUMAB IN ALZHEIMER‚ÄôS DISEASE OMG  $XBI $IBB $NBI,en,[],[],[],2,1,9,[],"['biib', 'xbi', 'ibb', 'nbi']",https://twitter.com/_B_I_O_T_E_C_H_/status/1186596603630620678,False,,0,,,,,,,,[],,,,
1186593328177012736,1186593328177012736,2019-10-22 16:11:09 IST,2019-10-22,16:11:09,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,$BIIB BIOGEN SHARES UP 19% !!! PREMARKET AFTER CO PLANS REGULATORY FILING FOR ADUCANUMAB IN ALZHEIMER‚ÄôS DISEASE WTF,en,[],[],[],2,1,5,[],['biib'],https://twitter.com/_B_I_O_T_E_C_H_/status/1186593328177012736,False,,0,,,,,,,,[],,,,
1186593294442213379,1186593294442213379,2019-10-22 16:11:01 IST,2019-10-22,16:11:01,+0530,857693619406467072,gualestrit,Gualestrit,,Biogen planea solicitar la aprobaci√≥n de su aducanumab para Alzheimer a la FDA tras un nuevo an√°lisis de sus ensayos cl√≠nicos en fase 3.  $BIIB +17.5% premarket   https://t.co/TLyPCi7eWX,es,[],['http://investors.biogen.com/news-releases/news-release-details/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease'],[],1,4,12,[],['biib'],https://twitter.com/gualestrit/status/1186593294442213379,False,,0,,,,,,,,[],,,,
1186592800521031680,1186592800521031680,2019-10-22 16:09:04 IST,2019-10-22,16:09:04,+0530,61342056,optionshawk,Joe Kunkle,,Oh Biogen $BIIB ... all those bull risk reversals positioned in Oct. expiry were expecting this news a few days earlier...,en,[],[],[],1,0,16,[],['biib'],https://twitter.com/OptionsHawk/status/1186592800521031680,False,,0,,,,,,,,[],,,,
1186589795448958976,1186589795448958976,2019-10-22 15:57:07 IST,2019-10-22,15:57:07,+0530,857693619406467072,gualestrit,Gualestrit,,Resultados üî• antes de la apertura:  ‚ñ™Ô∏è McDonald's $MCD ‚ñ™Ô∏è Procter &amp; Gamble $PG ‚ñ™Ô∏è Lockheed Martin $LMT ‚ñ™Ô∏è UPS $UPS ‚ñ™Ô∏è United Technologies $UTX ‚ñ™Ô∏è Biogen $BIIB ‚ñ™Ô∏è Hasbro $HAS ‚ñ™Ô∏è JetBlue $JBLU ‚ñ™Ô∏è Harley-Davidson $HOG ‚ñ™Ô∏è Kimberly-Clark $KMB ‚ñ™Ô∏è Travelers $TRV,en,[],[],[],2,17,32,[],"['mcd', 'pg', 'lmt', 'ups', 'utx', 'biib', 'has', 'jblu', 'hog', 'kmb', 'trv']",https://twitter.com/gualestrit/status/1186589795448958976,False,,0,,,,,,,,[],,,,
1185191511178272778,1184463055343751168,2019-10-18 19:20:50 IST,2019-10-18,19:20:50,+0530,1545630956,ionisdisrupts,Art,,@OTSociety @VArechavala @harvardmed @broadinstitute Another N=1 in #antisense.ü§ûü§û #JaciHermstad #ALS #otsmunich #RareDiseases #biotechnology @alsadvocacy @alsassociation @BPMonia  @ionispharma @biogen $IONS $BIIB  https://t.co/YPzz25o215,ht,"[{'screen_name': 'alsadvocacy', 'name': 'als advocacy', 'id': '21649697'}, {'screen_name': 'alsassociation', 'name': 'the als association', 'id': '21416670'}, {'screen_name': 'bpmonia', 'name': 'brett p. monia, ph.d.', 'id': '814262654655074304'}, {'screen_name': 'ionispharma', 'name': 'ionis pharma', 'id': '4448337313'}, {'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",['https://ktiv.com/2019/10/17/jaci-hermstad-continues-to-show-signs-of-progress-in-fight-against-als/'],[],0,1,7,"['antisense', 'jacihermstad', 'als', 'otsmunich', 'rarediseases', 'biotechnology']","['ions', 'biib']",https://twitter.com/IonisDisrupts/status/1185191511178272778,False,,0,,,,,,,,"[{'screen_name': 'OTSociety', 'name': 'Oligotherapeutics', 'id': '1596978572'}, {'screen_name': 'VArechavala', 'name': 'Virginia Arechavala', 'id': '55569332'}, {'screen_name': 'harvardmed', 'name': 'Harvard Medical School', 'id': '30862829'}, {'screen_name': 'broadinstitute', 'name': 'Broad Institute', 'id': '35306978'}]",,,,
1183753943245041664,1183753943245041664,2019-10-14 20:08:27 IST,2019-10-14,20:08:27,+0530,758386485846544384,realwillmeade,Will Meade,,Biogen $BIIB OCT$235 calls for 39 cents hot again this week Biogen,en,[],[],[],2,3,16,[],['biib'],https://twitter.com/realwillmeade/status/1183753943245041664,False,,0,,,,,,,,[],,,,
1182412023965147138,1182412023965147138,2019-10-11 03:16:09 IST,2019-10-11,03:16:09,+0530,758386485846544384,realwillmeade,Will Meade,,"On Monday a trader-hedge fund purchased 1500 $BIIB Oct11th $235 calls for $1.10 a $165,000 bet, 1393 of these are still in open interest and set to expire tomorrow. These Biogen $BIIB Oct11th $235 calls are now 10-20 cents Does somebody know something tomorrow?",en,[],[],[],9,7,41,[],"['biib', 'biib']",https://twitter.com/realwillmeade/status/1182412023965147138,False,,0,,,,,,,,[],,,,
1179061572620214278,1179061572620214278,2019-10-01 21:22:39 IST,2019-10-01,21:22:39,+0530,44438256,matthewherper,Matthew Herper,,"At Biogen, drug developer Al Sandrock gets a chance to take his shot  https://t.co/Aam1Hpy71D $BIIB",en,[],['https://www.statnews.com/2019/10/01/at-biogen-drug-developer-al-sandrock-gets-a-chance-to-take-his-shot/'],[],0,1,9,[],['biib'],https://twitter.com/matthewherper/status/1179061572620214278,False,,0,,,,,,,,[],,,,
1173935488979349505,1173935488979349505,2019-09-17 17:53:25 IST,2019-09-17,17:53:25,+0530,229246832,lifescivc,Bruce Booth,,Biogen‚Äôs IPF termination: The end of a 2+ decade saga of STX-100... the long winding road of novel drug R&amp;D... biology is always more complex and unpredictable than we think.  Sad day for IPF patients who remain in great need of new medicines $BIIB @Stromedix @michael_gilman,en,"[{'screen_name': 'stromedix', 'name': 'stromedix', 'id': '33021464'}, {'screen_name': 'michael_gilman', 'name': 'michael gilman', 'id': '47348249'}]",[],[],4,6,38,[],['biib'],https://twitter.com/LifeSciVC/status/1173935488979349505,False,,0,,,,,,,,[],,,,
1173933075010445317,1173933075010445317,2019-09-17 17:43:50 IST,2019-09-17,17:43:50,+0530,849093025884237825,sanctuary_bio,Wilson Cheung,,$BIIB In case you weren't familiar with the story...  Biogen humiliated yet again   https://t.co/WNxsR8BCpy,en,[],['https://xconomy.com/boston/2012/02/14/biogen-buys-stromedix-for-75m-regaining-fibrosis-drug/'],[],2,0,7,[],['biib'],https://twitter.com/Sanctuary_Bio/status/1173933075010445317,False,,0,,,,,,,,[],,,,
1172493507744976897,1172493507744976897,2019-09-13 18:23:30 IST,2019-09-13,18:23:30,+0530,943868448047816704,biotechmania,BiotechMania,,„Ç®„Éº„Ç∂„Ç§Ôºö3Êúà„ÅÆ„Ç¢„Éá„É•„Ç´„Éå„Éû„Éñ„ÅÆÈñãÁô∫‰∏≠Ê≠¢„Å´Á∂ö„Åç„ÄÅBiogen $BIIB „Å®ÂÖ±ÂêåÈñãÁô∫‰∏≠„ÅÆ„Ç¢„É´„ÉÑ„Éè„Ç§„Éû„ÉºÁóÖ„Å´ÂØæ„Åô„Çã„Ç®„É¨„É≥„Éô„Çª„Çπ„Çø„ÉÉ„Éà (E2609) Á¨¨‚Ö¢Áõ∏Ê≤ªÈ®ì‰∏≠Ê≠¢„ÄÇÂÖ±ÂêåÈñãÁô∫ÂìÅ„ÅßÊÆã„Çã„ÅØBAN2401„Å†„Åë„Å®„Å™„Çã„Åå„ÄÅÁô∫Ë°®„Åï„Çå„Å¶„ÅÑ„Çã„Éá„Éº„Çø„ÇíË¶ã„ÇãÈôê„Çä„Åì„Å°„Çâ„ÇÇ‰∏äÂ∏Ç„Åæ„ÅßËæø„ÇäÁùÄ„Åè„ÅÆ„ÅØ„Åã„Å™„ÇäÂé≥„Åó„ÅÑÂç∞Ë±°„ÄÇ  https://t.co/rgEZ0847JR  https://t.co/Q7MxhxgyIB,ja,[],['https://www.eisai.co.jp/news/2019/news201965.html'],['https://pbs.twimg.com/media/EEWIoUpX4AIGg8i.png'],1,76,125,[],['biib'],https://twitter.com/BiotechMania/status/1172493507744976897,False,,1,https://pbs.twimg.com/media/EEWIoUpX4AIGg8i.png,,,,,,,[],,,,
1172488839178461184,1172488839178461184,2019-09-13 18:04:57 IST,2019-09-13,18:04:57,+0530,102754598,johncendpts,John Carroll,,"It‚Äôs finally over: Biogen, Eisai scrap big Alzheimer‚Äôs PhIIIs after another BACE catastrophe raises safety fears $BIIB -1.3% (someone didn't know what was coming?)  https://t.co/vfgeDB82Hd",en,[],['https://endpts.com/its-finally-over-biogen-eisai-scrap-big-alzheimers-phiiis-after-another-bace-catastrophe-raises-safety-fears/'],[],1,7,9,[],['biib'],https://twitter.com/JohnCendpts/status/1172488839178461184,False,,0,,,,,,,,[],,,,
1164048735833399296,1164048735833399296,2019-08-21 11:07:00 IST,2019-08-21,11:07:00,+0530,3460109487,endpts,Endpoints News,,"Pfizer Foundation offers $2M in grants to #NGOs tackling antimicrobial resistance; Biogen, Invitae join forces to develop faster #SMA diagnostic  https://t.co/XB5Rcpappt $PFE $BIIB $NVTA",en,[],['https://endpts.com/pfizer-foundation-offers-2m-in-grants-to-ngos-tackling-antimicrobial-resistance-biogen-invitae-join-forces-to-develop-faster-sma-diagnostic/'],[],0,0,6,"['ngos', 'sma']","['pfe', 'biib', 'nvta']",https://twitter.com/endpts/status/1164048735833399296,False,,0,,,,,,,,[],,,,
1159474702210834433,1159474702210834433,2019-08-08 20:11:25 IST,2019-08-08,20:11:25,+0530,328280754,saitochung,David Saito-Chung,,"#biotech #stocks from  #SanDiego area have delivered too. GenProbe, Idec Pharmaceuticals come to mind @biogen $biib #investing #innovation #tech @IBD_DChung",en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'ibd_dchung', 'name': 'david chung', 'id': '1544227476'}]",[],[],0,1,4,"['biotech', 'stocks', 'sandiego', 'investing', 'innovation', 'tech']",['biib'],https://twitter.com/SaitoChung/status/1159474702210834433,False,https://twitter.com/RossHaber_/status/1159266968790323203,0,,,,,,,,[],,,,
1159253430357151744,1159253430357151744,2019-08-08 05:32:10 IST,2019-08-08,05:32:10,+0530,15752608,bosbizdon,Don Seiffert,,"After years as a rare disease drugmaker, Sarepta is expanding into a neurological disease that affects millions of people worldwide and has been dominated for years by its Cambridge neighbor, @biogen. By @BosBizAllison $BIIB $SRPT  https://t.co/DY335bD1N1",en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",['http://bizj.us/1py7ww'],[],5,10,45,[],"['biib', 'srpt']",https://twitter.com/BosBizDon/status/1159253430357151744,False,,0,,,,,,,,[],,,,
1153617188298928128,1153617188298928128,2019-07-23 16:15:45 IST,2019-07-23,16:15:45,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"""In May 2019 Biogen‚Äôs collaboration partner Eisai, Co., Ltd. dosed the first patient in the global Phase 3 study (Clarity AD) of BAN2401 in early Alzheimer¬¥s disease.‚Äù  Why?   $BIIB",en,[],[],[],6,3,16,[],['biib'],https://twitter.com/adamfeuerstein/status/1153617188298928128,False,,0,,,,,,,,[],,,,
1153614069728985088,1153614069728985088,2019-07-23 16:03:21 IST,2019-07-23,16:03:21,+0530,59393368,livesquawk,LiveSquawk,,Biogen 2Q Earnings: Raises FY Guidance $BIIB -Sees FY Rev: $14-$14.2B (prev saw $13.6B - $13.8B) -Sees FY Adj EPS: $31.5-$32.3 (prev saw $28-$29),en,[],[],[],0,8,7,[],['biib'],https://twitter.com/LiveSquawk/status/1153614069728985088,False,,0,,,,,,,,[],,,,
1149637700170895361,1149637700170895361,2019-07-12 16:42:41 IST,2019-07-12,16:42:41,+0530,102754598,johncendpts,John Carroll,,"Dear $BIIB: Time to kill your BACE program with Eisai. From Porges: ""news that Amgen and Novartis found negative effects from their medicine reinforces the dismal prospects for this target, and the folly of Biogen‚Äôs continued investment in this pathway.""  https://t.co/KODQR25sAt",en,[],['https://endpts.com/amgen-novartis-pile-on-new-fears-that-bace-could-be-a-dangerous-approach-to-alzheimers-a-field-left-to-biogen-eisai/'],[],3,8,12,[],['biib'],https://twitter.com/JohnCendpts/status/1149637700170895361,False,,0,,,,,,,,[],,,,
1149436113494401026,1149436113494401026,2019-07-12 03:21:39 IST,2019-07-12,03:21:39,+0530,102754598,johncendpts,John Carroll,,"This is just awful -- Amgen, Novartis pile on fears that BACE may be a dangerous approach to Alzheimer's ‚Äî a field left to Biogen/Eisai $BIIB  https://t.co/KODQR2n3Z3",en,[],['https://endpts.com/amgen-novartis-pile-on-new-fears-that-bace-could-be-a-dangerous-approach-to-alzheimers-a-field-left-to-biogen-eisai/'],[],1,3,7,[],['biib'],https://twitter.com/JohnCendpts/status/1149436113494401026,False,,0,,,,,,,,[],,,,
1147011595010289664,1147011595010289664,2019-07-05 10:47:29 IST,2019-07-05,10:47:29,+0530,401575573,dividendc2,dividendc2,,Mis TOP5 mejores compa√±√≠as - Healthcare -  Longevidad - largo plazo :  1: AbbVie Inc $ABBV  2: Amgen Inc $AMGN   3: Bristol-Myers Squibb Co $BMY  4: Medtronic PLC $MDT  5:  Biogen Inc $BIIB,ca,[],[],[],1,3,13,[],"['abbv', 'amgn', 'bmy', 'mdt', 'biib']",https://twitter.com/dividendc2/status/1147011595010289664,False,,0,,,,,,,,[],,,,
1145867214723198976,1145867214723198976,2019-07-02 07:00:07 IST,2019-07-02,07:00:07,+0530,227778014,biocentury,BioCentury,,Biogen's SMA therapy Spinraza yields long-term preservation of motor development and function on par with Zolgensma gene therapy data. $BIIB  https://t.co/FpHxg7ENTy,en,[],['https://buff.ly/2NqICGK'],[],0,7,13,[],['biib'],https://twitter.com/BioCentury/status/1145867214723198976,False,,0,,,,,,,,[],,,,
1143634982956666880,1143634982956666880,2019-06-26 03:10:02 IST,2019-06-26,03:10:02,+0530,16732770,cnbcfastmoney,CNBC's Fast Money,,POLL: Are you buying @petenajarian's Fast Pitch on Biogen? $BIIB,en,"[{'screen_name': 'petenajarian', 'name': 'pete najarian', 'id': '14292717'}]",[],[],14,4,8,[],['biib'],https://twitter.com/CNBCFastMoney/status/1143634982956666880,False,,0,,,,,,,,[],,,,
1131257454652792833,1131256098802012161,2019-05-22 23:26:09 IST,2019-05-22,23:26:09,+0530,758386485846544384,realwillmeade,Will Meade,,Billionaires Secret  Biogen Bull Call $BIIB Jan 2020 $300/$320 bull call spreads for $1.50 max payout of 1200% or 12x  For stock investors risk $17 (the low on $BIIB) to make $85 when and if Biogen fills back its gap at $320 a 5 to 1 Risk Reward  https://t.co/YeZ9SovYYp,en,[],[],['https://pbs.twimg.com/media/D7MIqDJXkAAMiXT.jpg'],0,0,32,[],"['biib', 'biib']",https://twitter.com/realwillmeade/status/1131257454652792833,False,,1,https://pbs.twimg.com/media/D7MIqDJXkAAMiXT.jpg,,,,,,,[],,,,
1130738888530649088,1130738888530649088,2019-05-21 13:05:33 IST,2019-05-21,13:05:33,+0530,401575573,dividendc2,dividendc2,,Mis TOP5 mejores compa√±√≠as - Healthcare -  Longevidad - largo plazo :  1: AbbVie Inc $ABBV  2: Amgen Inc $AMGN   3: Bristol-Myers Squibb Co $BMY  4: Medtronic PLC $MDT  5:  Biogen Inc $BIIB,ca,[],[],[],2,1,13,[],"['abbv', 'amgn', 'bmy', 'mdt', 'biib']",https://twitter.com/dividendc2/status/1130738888530649088,False,,0,,,,,,,,[],,,,
1128261488286814208,1128261488286814208,2019-05-14 17:01:15 IST,2019-05-14,17:01:15,+0530,102754598,johncendpts,John Carroll,,"We have come to the crossroads, finally -- Alzheimer‚Äôs R&amp;D projects sidelined as Biogen‚Äôs aducanumab shock shakes researchers to the core of their beliefs $BIIB  https://t.co/Es8BPK6gg3",en,[],['https://endpts.com/alzheimers-rd-projects-sidelined-as-biogens-aducanumab-shock-shakes-researchers-to-the-core-of-their-beliefs/'],[],1,7,13,[],['biib'],https://twitter.com/JohnCendpts/status/1128261488286814208,False,,0,,,,,,,,[],,,,
1126064281051631617,1126064281051631617,2019-05-08 15:30:20 IST,2019-05-08,15:30:20,+0530,3290364847,statnews,STAT,,"A neurology conference offered plenty of answers about SMA treatments from Novartis, Roche, and Biogen ‚Äî but left questions about which will lead the future market. $NVS $RHHBY $BIIB  https://t.co/N3YkjsiJ39",en,[],['https://buff.ly/2Q1vfdT'],[],1,6,7,[],"['nvs', 'rhhby', 'biib']",https://twitter.com/statnews/status/1126064281051631617,False,,0,,,,,,,,[],,,,
1122027183797690368,1122027183797690368,2019-04-27 12:08:21 IST,2019-04-27,12:08:21,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,EVERCORE UMER RAFFAT just hosted $BIIB Biogen mgmt on an NDR M&amp;A thoughts: ‚Äúnot panicked‚Äù to do a large deal I asked if the next sizable deal might be outside of neurology they are very focused and looking both in neurology and adjacencies trying to be patient and very careful,en,[],[],[],0,2,5,[],['biib'],https://twitter.com/_B_I_O_T_E_C_H_/status/1122027183797690368,False,,0,,,,,,,,[],,,,
1121088580540162049,1121088580540162049,2019-04-24 21:58:41 IST,2019-04-24,21:58:41,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Biogen sees no need for big changes in wake of Alzheimer‚Äôs drug setback  https://t.co/8PdeACtAXL I wrote 150 words, might have been too many, given $BIIB seems to feel like all is well.",en,[],['https://www.statnews.com/2019/04/24/biogen-sees-no-need-for-big-changes-in-wake-of-alzheimers-drug-setback/'],[],2,4,10,[],['biib'],https://twitter.com/adamfeuerstein/status/1121088580540162049,False,,0,,,,,,,,[],,,,
1113060685477527552,1113060685477527552,2019-04-02 18:18:41 IST,2019-04-02,18:18:41,+0530,359568042,drewqjoseph,Andrew Joseph,,"Biogen $BIIB says it won't provide aducanumab from its halted trial to Alzheimer's patients, despite FDA's recent expanded access nudge. That's a tidbit in the great @NicholasFlorko weekly newsletter on DC health policy -- sign up here:  https://t.co/2aYOp5FBbk  https://t.co/5pljgAU0PX",en,"[{'screen_name': 'nicholasflorko', 'name': 'nicholas florko', 'id': '325698693'}]",['https://www.statnews.com/signup/'],['https://pbs.twimg.com/media/D3JiZyEU4AAcUE-.png'],1,11,11,[],['biib'],https://twitter.com/DrewQJoseph/status/1113060685477527552,False,,1,https://pbs.twimg.com/media/D3JiZyEU4AAcUE-.png,,,,,,,[],,,,
1112685273991786496,1112685273991786496,2019-04-01 17:26:56 IST,2019-04-01,17:26:56,+0530,37718217,thedomino,Dominic Chu,,Performance since Christmas Eve Carnage for markets:  Gold +2% iShares 20+ Yr Treasury $TLT +4% S&amp;P 500 +21% Nasdaq Comp +25% Amazon $AMZN +33% WTI Crude Oil +42% Chipotle $CMG +84% Macy's $M -15% Biogen $BIIB -15% Kraft Heinz $KHC -23%  #NoJoke on this #AprilFools @cnbc,en,"[{'screen_name': 'cnbc', 'name': 'cnbc', 'id': '20402945'}]",[],[],5,11,13,"['nojoke', 'aprilfools']","['tlt', 'amzn', 'cmg', 'm', 'biib', 'khc']",https://twitter.com/TheDomino/status/1112685273991786496,False,,0,,,,,,,,[],,,,
1110999796863696896,1110999796863696896,2019-03-28 01:49:27 IST,2019-03-28,01:49:27,+0530,15568127,themotleyfool,The Motley Fool,,"So many great topics on today's @MFIndustryFocus show: Biogen's big pipeline blow up, the latest gene therapy M&amp;A news, and updates on the Bristol-Myers Squibb &amp; Celgene drama.  Subscribe wherever you get podcasts and Fool On! $BIIB $BMY $CELG $TMO  https://t.co/o8VtfPSle3",en,"[{'screen_name': 'mfindustryfocus', 'name': 'industry focus', 'id': '1548736957'}]",[],[],0,2,10,[],"['biib', 'bmy', 'celg', 'tmo']",https://twitter.com/themotleyfool/status/1110999796863696896,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1110999508685602819/pu/img/0auPrhFekyIaNXr2.jpg,,,,,,,[],,,,
1110141090433257472,1110141090433257472,2019-03-25 16:57:16 IST,2019-03-25,16:57:16,+0530,1436391649,pickingmyown,PantherFan,,"$AMRN $biib Biogen has a stench of desperation combined with confusion implementing $5bil buyback plan? Totally clueless as to what to do. Here's a clue. Go buy somebody and fast, and make AMRN your first call.  Doubt you get them but make the call to JT anyway.",en,[],[],[],3,1,8,[],"['amrn', 'biib']",https://twitter.com/PickingMyOwn/status/1110141090433257472,False,,0,,,,,,,,[],,,,
1110137863121842176,1110137863121842176,2019-03-25 16:44:26 IST,2019-03-25,16:44:26,+0530,19717430,zbiotech,zach,,*BIOGEN TO BUY BACK UP TO $5B SHARES  ‚Äòthe typical‚Äô  $BIIB,en,[],[],[],2,3,23,[],['biib'],https://twitter.com/zbiotech/status/1110137863121842176,False,,0,,,,,,,,[],,,,
1110137125289250816,1110137125289250816,2019-03-25 16:41:30 IST,2019-03-25,16:41:30,+0530,61342056,optionshawk,Joe Kunkle,,Biogen $BIIB falls into the Celgene/Gilead dead pipeline trap move and announces a $5B buyback,en,[],[],[],2,4,14,[],['biib'],https://twitter.com/OptionsHawk/status/1110137125289250816,False,,0,,,,,,,,[],,,,
1109971224426397697,1109971224426397697,2019-03-25 05:42:16 IST,2019-03-25,05:42:16,+0530,3150211629,thlizrd,thlizrd,,"$SRPT $BIIB $SAGE $IONS Every Sarepta investor should read this short 9-paragraph Bloomberg report ....  ""[Sarepta] is a more logical fit for Biogen, which has turned Spinraza into a blockbuster in spinal-muscular atrophy.""   Giddy-up!! ---thlizrdü§†   https://t.co/miqsoyIZFN",en,[],['https://www.bnnbloomberg.ca/a-28-billion-shopping-list-for-biogen-1.1233083'],[],2,2,15,[],"['srpt', 'biib', 'sage', 'ions']",https://twitter.com/thlizrd/status/1109971224426397697,False,,0,,,,,,,,[],,,,
1109469789548957696,1109469789548957696,2019-03-23 20:29:45 IST,2019-03-23,20:29:45,+0530,102754598,johncendpts,John Carroll,,Is a severely damaged Biogen ($BIIB -32%) looking to shed its ties to a controversial development partner?  https://t.co/Mc4H554fBy,en,[],['https://endpts.com/is-a-severely-damaged-biogen-looking-to-shed-its-ties-to-a-controversial-development-partner/'],[],1,4,9,[],[],https://twitter.com/JohnCendpts/status/1109469789548957696,False,,0,,,,,,,,[],,,,
1109186660435222530,1109186660435222530,2019-03-23 01:44:42 IST,2019-03-23,01:44:42,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Some late Friday news --&gt; $BIIB - Eisai partnership may be hitting a rough patch following Alzheimer‚Äôs drug blowup  https://t.co/XKCXFKJGR4 Speculative but you have to read the Biogen statement sent to me re: BAN2401. Woof!,en,[],['https://www.statnews.com/2019/03/22/biogen-eisai-partnership-alzheimers-drug-blowup/'],[],1,14,16,[],['biib'],https://twitter.com/adamfeuerstein/status/1109186660435222530,False,,0,,,,,,,,[],,,,
1109054711234289665,1109054711234289665,2019-03-22 17:00:23 IST,2019-03-22,17:00:23,+0530,2260978466,big4biobos,Big4Bio:Boston,,Sage‚Äôs CEO reflects on progress treating postpartum depression and what Biogen‚Äôs big #Alzheimers failure means  https://t.co/EInwRNeEEz via @statnews @alissa_ambrose @adamfeuerstein @matthewherper $SAGE $BIIB,en,"[{'screen_name': 'statnews', 'name': 'stat', 'id': '3290364847'}, {'screen_name': 'alissa_ambrose', 'name': 'alissa ambrose', 'id': '198514721'}, {'screen_name': 'adamfeuerstein', 'name': 'adam feuerstein', 'id': '102094857'}, {'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['https://www.statnews.com/2019/03/22/sages-ceo-postpartum-depression-biogens-alzheiemers/'],[],0,4,5,['alzheimers'],"['sage', 'biib']",https://twitter.com/big4bioBOS/status/1109054711234289665,False,,0,,,,,,,,[],,,,
1109048243231621120,1109048243231621120,2019-03-22 16:34:40 IST,2019-03-22,16:34:40,+0530,112872946,biostocks,Bio Stocks‚Ñ¢,,$BIIB Biogen‚Äôs Next Move Could Be an Acquisition  https://t.co/v5qx8nSdDx #biotech,en,[],['https://www.barrons.com/articles/biogens-next-move-could-be-an-acquisition-51553252400'],[],2,8,7,['biotech'],['biib'],https://twitter.com/BioStocks/status/1109048243231621120,False,,0,,,,,,,,[],,,,
1108847421503746050,1108833698487693313,2019-03-22 03:16:41 IST,2019-03-22,03:16:41,+0530,225911893,predatordiaries,Andy Smith,,"@roncohenshair @biogen Don't make them sound like charities Ron, $BIIB's stockholders took all the risk, while $BIIB's CMO raked in a $10m stock sale after the the hyped interim Phase I data announcement alone.",en,[],[],[],2,1,9,[],"['biib', 'biib']",https://twitter.com/PredatorDiaries/status/1108847421503746050,False,,0,,,,,,,,"[{'screen_name': 'roncohenshair', 'name': 'Ron Cohen Acorda CEO', 'id': '2420618906'}, {'screen_name': 'biogen', 'name': 'Biogen', 'id': '155650832'}]",,,,
1108846037995831296,1108846037995831296,2019-03-22 03:11:11 IST,2019-03-22,03:11:11,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,ARM Transcript  $SGMO comments on $BIIB  Biogen and the end of amyloid hope   https://t.co/MEZTeQvpx2,en,[],['https://www.investorvillage.com/smbd.asp?mb=1933&mn=123433&pt=msg&mid=19265129'],[],2,8,10,[],"['sgmo', 'biib']",https://twitter.com/_B_I_O_T_E_C_H_/status/1108846037995831296,False,,0,,,,,,,,[],,,,
1108832779075272704,1108832779075272704,2019-03-22 02:18:30 IST,2019-03-22,02:18:30,+0530,116229964,sachakin,Sacha Pouget,,"Alzheimer = 99.9% d'√©chec en clinique. Pourtant, le march√© y a cru pour Biogen $BIIB. R√©sultat: sa capitalisation boursi√®re perd 20 Milliards $ en une s√©ance ce 21 Mars... apr√®s un √©chec en phase clinique.",fr,[],[],[],2,5,13,[],['biib'],https://twitter.com/Sachakin/status/1108832779075272704,False,,0,,,,,,,,[],,,,
1108817805015687168,1108817805015687168,2019-03-22 01:19:00 IST,2019-03-22,01:19:00,+0530,262365030,atulbutte,Atul Butte,,"Holy OUCH!  $BIIB Biogen stock plunges 28%, or in Silicon Valley units, they shed 13 unicorns of valuation today!  Yes, drug discovery is hard.   https://t.co/NSSJAfv7Wz",en,[],['https://buff.ly/2FnZdDR'],[],0,5,9,[],['biib'],https://twitter.com/atulbutte/status/1108817805015687168,False,,0,,,,,,,,[],,,,
1108798524001566723,1108798524001566723,2019-03-22 00:02:23 IST,2019-03-22,00:02:23,+0530,61342056,optionshawk,Joe Kunkle,,Biogen $BIIB afternoon spread buys 400 January $300 calls at $7.35 and sells 800 of the $200 puts for $13.80,en,[],[],[],1,2,15,[],['biib'],https://twitter.com/OptionsHawk/status/1108798524001566723,False,,0,,,,,,,,[],,,,
1108752946349645824,1108752946349645824,2019-03-21 21:01:16 IST,2019-03-21,21:01:16,+0530,153961690,pattie_jabbaz,Pattie Jabbaz Consulting,,"Como puede pasar q las acciones d $Biogen bajan casi 29% y el etf $LABU q bajaba el 4 % en pre mkt, ahora c la baja q persiste en $BIIB c 29%, $LABU recupero y esta c suba del 3 %, como puede esto suceder?",es,[],[],[],1,1,6,[],"['biogen', 'labu', 'biib', 'labu']",https://twitter.com/pattie_jabbaz/status/1108752946349645824,False,,0,,,,,,,,[],,,,
1108749312358518786,1108749312358518786,2019-03-21 20:46:50 IST,2019-03-21,20:46:50,+0530,46437396,ebcapital,Todd Campbell,,"Biogen‚Äôs Big Bet in Alzheimer‚Äôs Disease Is a Bust @themotleyfool #stocks $BIIB , $LLY, $PFE , $JNJ #biotech #health  https://t.co/27Iu4zCoqR",en,"[{'screen_name': 'themotleyfool', 'name': 'the motley fool', 'id': '15568127'}]",['https://www.fool.com/investing/2019/03/21/biogens-big-bet-in-alzheimers-disease-is-a-bust.aspx'],[],1,3,6,"['stocks', 'biotech', 'health']","['biib', 'lly', 'pfe', 'jnj']",https://twitter.com/ebcapital/status/1108749312358518786,False,,0,,,,,,,,[],,,,
1108739138377957382,1108739138377957382,2019-03-21 20:06:24 IST,2019-03-21,20:06:24,+0530,295746612,faycortez,Michelle Fay Cortez,,"For people who wonder why drugs are so expensive, here's the answer. $BIIB spent more than $800 million on this compound in the past three years. (Note: I do think drugs are too expensive). Biogen shares plunge after Alzheimer's drug setback  https://t.co/Ly5qRogXc8 via @business",en,"[{'screen_name': 'business', 'name': 'bloomberg', 'id': '34713362'}]",['https://www.bloomberg.com/news/articles/2019-03-21/biogen-halts-study-of-alzheimer-s-treatment-as-study-falls-short'],[],2,23,41,[],['biib'],https://twitter.com/FayCortez/status/1108739138377957382,False,,0,,,,,,,,[],,,,
1108735192561152002,1108735192561152002,2019-03-21 19:50:43 IST,2019-03-21,19:50:43,+0530,229246832,lifescivc,Bruce Booth,,Biogen has lost more value this morning (~$17B) than was raised in all 130+ biotech IPOs since Jan 2015 combined (~$15B)... Ouch.  $BIIB,en,[],[],[],18,133,299,[],['biib'],https://twitter.com/LifeSciVC/status/1108735192561152002,False,,0,,,,,,,,[],,,,
1108724577738330112,1108724577738330112,2019-03-21 19:08:33 IST,2019-03-21,19:08:33,+0530,816437861499240453,ryansttrader,Ryan Davidson,,$BIIB It‚Äôs time for Biogen to smell the Coffee and begin M/A to keep company afloat. The following are likely: $QURE $NBIX $CLVS $SRPT,en,[],[],[],0,0,13,[],"['biib', 'qure', 'nbix', 'clvs', 'srpt']",https://twitter.com/RyanSTTrader/status/1108724577738330112,False,,0,,,,,,,,[],,,,
1108717095083220992,1108717095083220992,2019-03-21 18:38:49 IST,2019-03-21,18:38:49,+0530,15281391,thestreet,TheStreet,,Biogen $BIIB down over 27% premarket  after Alzheimer's drug is scrapped,da,[],[],[],0,6,8,[],['biib'],https://twitter.com/TheStreet/status/1108717095083220992,False,,0,,,,,,,,[],,,,
1108715573452685318,1108715573452685318,2019-03-21 18:32:46 IST,2019-03-21,18:32:46,+0530,61342056,optionshawk,Joe Kunkle,,"Biogen $BIIB better start putting some cash to work, Alzheimer's fail, MS biz deteriorating, one Co. been thinking a smart target would be $AXSM but bigger targets I like $SAGE $NBIX",en,[],[],[],3,0,11,[],"['biib', 'axsm', 'sage', 'nbix']",https://twitter.com/OptionsHawk/status/1108715573452685318,False,,0,,,,,,,,[],,,,
1108712535400710144,1108712535400710144,2019-03-21 18:20:41 IST,2019-03-21,18:20:41,+0530,849093025884237825,sanctuary_bio,Wilson Cheung,,"don't get me wrong, this is sad news for patients.   But after how @biogen talked up aduca in 2015, and then BAN2401 last year, it is hard to feel anything other than sheer contempt for that mgmt team $BIIB",en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],[],3,1,16,[],['biib'],https://twitter.com/Sanctuary_Bio/status/1108712535400710144,False,https://twitter.com/sxbegle/status/1108703861076824065,0,,,,,,,,[],,,,
1108709404055080960,1108709404055080960,2019-03-21 18:08:15 IST,2019-03-21,18:08:15,+0530,15752608,bosbizdon,Don Seiffert,,Obv. I‚Äôm not a scientist in the least. But I agree with this on a purely moral basis. @Biogen made a huge bet that could have benefitted humanity immeasurably. The fact that they lost doesn‚Äôt mean they shouldn‚Äôt have. $biib,en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],[],1,4,11,[],['biib'],https://twitter.com/BosBizDon/status/1108709404055080960,False,https://twitter.com/michael_gilman/status/1108695376486457344,0,,,,,,,,[],,,,
1108704993245360128,1108704993245360128,2019-03-21 17:50:43 IST,2019-03-21,17:50:43,+0530,801116888,cfromhertz,Christian Fromhertz,,$BIIB *BIOGEN FAIR VALUE $241 AT CITI WITHOUT ALZHEIMER'S,en,[],[],[],0,4,8,[],['biib'],https://twitter.com/cfromhertz/status/1108704993245360128,False,,0,,,,,,,,[],,,,
1108704370609324033,1108704370609324033,2019-03-21 17:48:15 IST,2019-03-21,17:48:15,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @SangamoTx @BoisselStephane @AdrianWoolfson  Delete all your prepared notes for today's webcast. We don't want to hear a repetition of what was already said. See what happened to $BIIB @biogen  Today give us an update on the emerging #tau pipeline in CNS &amp; #Alzheimers,en,"[{'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}, {'screen_name': 'boisselstephane', 'name': 'stephane boissel', 'id': '2580053524'}, {'screen_name': 'adrianwoolfson', 'name': 'adrianwoolfson', 'id': '393682087'}, {'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],[],0,4,11,"['tau', 'alzheimers']",['biib'],https://twitter.com/Biotech2050/status/1108704370609324033,False,,0,,,,,,,,[],,,,
1108699818015248386,1108699818015248386,2019-03-21 17:30:09 IST,2019-03-21,17:30:09,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,$BIIB @biogen For your attention: $SGMO @SangamoTx has an emerging #tau pipeline and will soon seek partners,en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}]",[],[],0,3,13,['tau'],"['biib', 'sgmo']",https://twitter.com/Biotech2050/status/1108699818015248386,False,https://twitter.com/_B_I_O_T_E_C_H_/status/997879447054356481,0,,,,,,,,[],,,,
1108696391377960966,1108696391377960966,2019-03-21 17:16:32 IST,2019-03-21,17:16:32,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,can we finaly do the $SGMO #Alzheimer deal in ANTI-#TAU ? BETA _ AMYLOID IS GOIG NOWHERE ! $BIIB BIOGEN AND EISAI TO #DISCONTINUE PHASE 3 ENGAGE AND EMERGE TRIALS OF #ADUCANUMAB IN ALZHEIMER'S DISEASE,en,[],[],[],0,3,7,"['alzheimer', 'tau', 'discontinue', 'aducanumab']","['sgmo', 'biib']",https://twitter.com/_B_I_O_T_E_C_H_/status/1108696391377960966,False,,0,,,,,,,,[],,,,
1108694027430514689,1108694027430514689,2019-03-21 17:07:09 IST,2019-03-21,17:07:09,+0530,37718217,thedomino,Dominic Chu,,"Biogen $BIIB beatdown...shares halted premarket, already -25%, on news that it &amp; Eisai will discontinue later stage trials of experimental Alzheimer's treatment.   https://t.co/9dApu87s62  @cnbc",en,"[{'screen_name': 'cnbc', 'name': 'cnbc', 'id': '20402945'}]",['https://www.cnbc.com/quotes/?symbol=biib&qsearchterm=biib'],[],0,3,7,[],['biib'],https://twitter.com/TheDomino/status/1108694027430514689,False,,0,,,,,,,,[],,,,
1108693989954326529,1108693989954326529,2019-03-21 17:07:00 IST,2019-03-21,17:07:00,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Biogen halts study of closely watched Alzheimer‚Äôs drug, a blow to hopes for new treatment  https://t.co/ZA7wnzVMLm $BIIB",en,[],['https://www.statnews.com/2019/03/21/biogen-eisai-alzheimer-trial-stopped/'],[],8,37,60,[],['biib'],https://twitter.com/adamfeuerstein/status/1108693989954326529,False,,0,,,,,,,,[],,,,
1108693114263343104,1108691545828540416,2019-03-21 17:03:31 IST,2019-03-21,17:03:31,+0530,857693619406467072,gualestrit,Gualestrit,,Biogen reanuda su cotizaci√≥n premarket con una ca√≠da de m√°s del 25%.  $BIIB,es,[],[],[],0,0,13,[],['biib'],https://twitter.com/gualestrit/status/1108693114263343104,False,,0,,,,,,,,[],,,,
1108691545828540416,1108691545828540416,2019-03-21 16:57:17 IST,2019-03-21,16:57:17,+0530,857693619406467072,gualestrit,Gualestrit,,"Biogen suspendida de cotizaci√≥n por anuncio de noticia importante.  Ha decidido suspender indefinidamente el ensayo cl√≠nico en fase 3 de Aducanumab, su medicamento contra el Alzheimer.  $BIIB",es,[],[],[],2,4,9,[],['biib'],https://twitter.com/gualestrit/status/1108691545828540416,False,,0,,,,,,,,[],,,,
1108684861890543616,1108684861890543616,2019-03-21 16:30:44 IST,2019-03-21,16:30:44,+0530,223677515,buysidebio,ct,,$BIIB BIOGEN &amp; EISAI TO STOP PHASE 3 ADUCANUMAB TRIALS IN ALZHEIMER‚ÄôS,de,[],[],[],1,12,20,[],['biib'],https://twitter.com/buysidebio/status/1108684861890543616,False,,0,,,,,,,,[],,,,
1108684771901755392,1108684771901755392,2019-03-21 16:30:22 IST,2019-03-21,16:30:22,+0530,61342056,optionshawk,Joe Kunkle,,"Biogen $BIIB to discontinue the global Phase 3 trials, ENGAGE and EMERGE",en,[],[],[],1,2,5,[],['biib'],https://twitter.com/OptionsHawk/status/1108684771901755392,False,,0,,,,,,,,[],,,,
1108684760971444225,1108684760971444225,2019-03-21 16:30:20 IST,2019-03-21,16:30:20,+0530,884391852119642112,trading_mz,Mz Trading,,Biogen Inc.: Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer‚Äôs Disease  $BIIB  Holy...,en,[],[],[],4,3,5,[],['biib'],https://twitter.com/trading_mz/status/1108684760971444225,False,,0,,,,,,,,[],,,,
1106582588293029888,1106582588293029888,2019-03-15 21:17:03 IST,2019-03-15,21:17:03,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$SGMO is beefing up its cell therapy team to grow the CAR-Tregs portfolio. Jason Fontenot will now lead that effort, including a partnership with $SNY and $GILD $KITE for hemoglobinopathies and cancer respectively. He is ex immusoft, $Juno and Biogen $BIIB  https://t.co/1BhaVog5XD",en,[],['https://endpts.com/astrazeneca-vet-jennifer-butler-takes-charge-of-innate-pharmas-us-biz-c4-raids-nibr/'],[],1,4,9,[],"['sgmo', 'sny', 'gild', 'kite', 'juno', 'biib']",https://twitter.com/_B_I_O_T_E_C_H_/status/1106582588293029888,False,,0,,,,,,,,[],,,,
1105281863801810945,1105281863801810945,2019-03-12 07:08:26 IST,2019-03-12,07:08:26,+0530,3426014292,semodough,dough,,$BIIB Biogen: The Phase III trial (NCT02623699) evaluating BIIB067 in adults with Inherited Amyotrophic Lateral Sclerosis (ALS) has increased its estimated patient enrollment from 84 to 144 patients.,en,[],[],[],2,1,10,[],['biib'],https://twitter.com/semodough/status/1105281863801810945,False,,0,,,,,,,,[],,,,
1102551092389470208,1102551092389470208,2019-03-04 18:17:19 IST,2019-03-04,18:17:19,+0530,632341632,andybiotech,Andy Biotech,,$AGTC vs $NITE:  That feeling when $BIIB dumps you to buy another ophthalmology gene therapy company...  Biogen can't even wait for the termination to become effective!  https://t.co/y3Twe3QHll,en,[],[],['https://pbs.twimg.com/media/D00ME5EWkAIGoP8.jpg'],4,3,34,[],"['agtc', 'nite', 'biib']",https://twitter.com/AndyBiotech/status/1102551092389470208,False,,1,https://pbs.twimg.com/media/D00ME5EWkAIGoP8.jpg,,,,,,,[],,,,
1102529214799065089,1102529214799065089,2019-03-04 16:50:23 IST,2019-03-04,16:50:23,+0530,61342056,optionshawk,Joe Kunkle,,"Another gene therapy deal at a healthy 70% premium, Biogen $BIIB acquiring $NITE",en,[],[],[],0,3,7,[],"['biib', 'nite']",https://twitter.com/OptionsHawk/status/1102529214799065089,False,,0,,,,,,,,[],,,,
1102525475841327104,1102525475841327104,2019-03-04 16:35:32 IST,2019-03-04,16:35:32,+0530,84402174,street_insider,Streetinsider.com,,Biogen $BIIB to Acquire Nightstar Therapeutics $NITE for $25.50/Sh in Deal Valued at Approx. $800M  https://t.co/atpuOjvLIL,en,[],['https://www.streetinsider.com/Corporate+News/Biogen+%28BIIB%29+to+Acquire+Nightstar+Therapeutics+%28NITE%29+for+%2425.50Sh+in+Deal+Valued+at+Approx.+%24800M/15208711.html'],[],0,8,7,[],"['biib', 'nite']",https://twitter.com/Street_Insider/status/1102525475841327104,False,,0,,,,,,,,[],,,,
1102514877011238912,1102514877011238912,2019-03-04 15:53:25 IST,2019-03-04,15:53:25,+0530,43901312,bylisau,ByLisaU,,Biogen must have seen something in Nightstars less than clear data last year to fork out $800M in cash - a 65% premium. Here is my take on that data. $BIIB $NITE  https://t.co/sIaeRuoYBK,en,[],['http://www.evaluate.com/vantage/articles/news/snippets/nightstar-investors-seek-more-clarity'],[],3,7,17,[],"['biib', 'nite']",https://twitter.com/ByLisaU/status/1102514877011238912,False,,0,,,,,,,,[],,,,
1102509512571916289,1102509512571916289,2019-03-04 15:32:06 IST,2019-03-04,15:32:06,+0530,174385219,mariogabelli,Mario Gabelli,,Merger Monday ....Biogen ( BIIB ) Buying London based Nightstar Theropeutics ( NITE) for $25.50 cash / shr ‚Äî‚Äîvs $15.16 close,en,[],[],[],0,0,6,[],[],https://twitter.com/MarioGabelli/status/1102509512571916289,False,,0,,,,,,,,[],,,,
1102482248899674112,1102482248899674112,2019-03-04 13:43:45 IST,2019-03-04,13:43:45,+0530,126416038,odibro,Odi Bruckman,,Biogen to acquire Nightstar Therapeutics for $25.5/share $800M in cash to establish clinical pipeline of gene therapy candidates in ophthalmology. ~ 65% premium $BIIB $NITE  https://t.co/QQSwFtXFpn,en,[],['http://investors.biogen.com/news-releases/news-release-details/biogen-announces-agreement-acquire-nightstar-therapeutics'],[],4,38,67,[],"['biib', 'nite']",https://twitter.com/odibro/status/1102482248899674112,False,,0,,,,,,,,[],,,,
1102464283655499776,1102464283655499776,2019-03-04 12:32:22 IST,2019-03-04,12:32:22,+0530,439377281,boerseger,BioGer,,$BIIB $NITE BIOGEN TO ACQUIRE NIGHTSTAR THERAPEUTICS FOR $25.50 PER SHARE,en,[],[],[],1,3,8,[],"['biib', 'nite']",https://twitter.com/BoerseGer/status/1102464283655499776,False,,0,,,,,,,,[],,,,
1093257650299559936,1093257650299559936,2019-02-07 02:48:30 IST,2019-02-07,02:48:30,+0530,31546412,tradehawk,TradeHawk,,$BIIB $MYL Biogen falling on institution of '514 Tecfidera IPR patent challenge trial by Mylan  https://t.co/J7zOyZGvhE,et,[],['https://www.scribd.com/document/399061281/Mylan-vs-Biogen-514-Tecfidera-IPR-Institution'],[],1,6,9,[],"['biib', 'myl']",https://twitter.com/TradeHawk/status/1093257650299559936,False,,0,,,,,,,,[],,,,
1092058852583985152,1092058852583985152,2019-02-03 19:24:54 IST,2019-02-03,19:24:54,+0530,1069486704,wolfmetric,Wolfmetric,,Sarissa Capital adding $20.5M in Biogen $BIIB stock last week at $325-$330 range remains their top holding,en,[],[],[],1,0,9,[],['biib'],https://twitter.com/Wolfmetric/status/1092058852583985152,False,,0,,,,,,,,[],,,,
1090597974823108609,1090597974823108609,2019-01-30 18:39:54 IST,2019-01-30,18:39:54,+0530,102754598,johncendpts,John Carroll,,"Hello, Biogen. Who's that knocking on your door? $BIIB -4%  https://t.co/bjei5He9cf",en,[],['https://endpts.com/roche-pulls-another-major-piece-out-of-the-wobbly-alzheimers-jenga-shuttering-crenezumab-phiiis/'],[],2,3,6,[],['biib'],https://twitter.com/JohnCendpts/status/1090597974823108609,False,,0,,,,,,,,[],,,,
1081381870217109506,1081381870217109506,2019-01-05 08:18:23 IST,2019-01-05,08:18:23,+0530,2182269975,chrisnasveschuk,Chris Nasveschuk,,Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions Nasdaq:BIIB  https://t.co/KYdnQNfC7s,en,[],['https://globenewswire.com/news-release/2019/01/04/1680580/0/en/Biogen-and-C4-Therapeutics-Enter-into-Strategic-Collaboration-to-Discover-and-Develop-Potential-New-Treatments-for-Neurological-Conditions.html'],[],0,1,6,[],[],https://twitter.com/ChrisNasveschuk/status/1081381870217109506,False,,0,,,,,,,,[],,,,
1069284291673300992,1069284291673300992,2018-12-02 23:06:56 IST,2018-12-02,23:06:56,+0530,1003002933376700422,aoifemlbrennan,Aoifemlbrennan,,Kudos to Biogen for all they are doing to foster STEM education locally. One of my fondest memories of my time at BIIB was the opportunity to volunteer in the community lab.,en,[],[],[],0,0,9,[],[],https://twitter.com/aoifemlbrennan/status/1069284291673300992,False,https://twitter.com/biogen/status/1069245010577637376,0,,,,,,,,[],,,,
1047557456891731969,1047557456891731969,2018-10-04 00:12:15 IST,2018-10-04,00:12:15,+0530,102754598,johncendpts,John Carroll,,"@BrianSkorney likes Roche's chances on risdiplam, added: Genentech takes aim at Biogen and Novartis, highlighting an early look at positive results for their oral SMA drug from PTC $BIIB $NVS $PTCT  https://t.co/CddsDy1aMO",en,[],['https://endpts.com/genentech-takes-aim-at-biogen-and-novartis-highlighting-an-early-look-at-positive-results-for-their-oral-sma-drug-from-ptc/'],[],0,1,5,[],"['biib', 'nvs', 'ptct']",https://twitter.com/JohnCendpts/status/1047557456891731969,False,,0,,,,,,,,[],,,,
1043165780932812800,1043165780932812800,2018-09-21 21:21:17 IST,2018-09-21,21:21:17,+0530,61342056,optionshawk,Joe Kunkle,,Biogen $BIIB buyer of 140 Oct. 26th (W) $360 OTM calls for $5.60,en,[],[],[],1,1,12,[],['biib'],https://twitter.com/OptionsHawk/status/1043165780932812800,False,,0,,,,,,,,[],,,,
1029348483101220864,1029348483101220864,2018-08-14 18:16:17 IST,2018-08-14,18:16:17,+0530,102754598,johncendpts,John Carroll,,Biogen‚Äôs big breakthrough drug Spinraza runs into a barrier as NICE turns thumbs down on reimbursement $BIIB  https://t.co/DHv4yjtRKG,en,[],['https://endpts.com/biogens-big-breakthrough-drug-spinraza-runs-into-a-barrier-as-nice-turns-thumbs-down-on-reimbursement/'],[],2,6,9,[],['biib'],https://twitter.com/JohnCendpts/status/1029348483101220864,False,,0,,,,,,,,[],,,,
1027635920974098432,1027635920974098432,2018-08-10 00:51:10 IST,2018-08-10,00:51:10,+0530,102754598,johncendpts,John Carroll,,Top story today Biogen‚Äôs high-stakes Alzheimer‚Äôs gamble is being roasted by the experts. Is the amyloid beta theory dead? $BIIB - 0.62%  https://t.co/knBwVyLuJQ,en,[],['https://endpts.com/biogens-high-stakes-alzheimers-gamble-is-being-roasted-by-the-experts-is-the-amyloid-beta-theory-dead/'],[],3,4,11,[],['biib'],https://twitter.com/JohnCendpts/status/1027635920974098432,False,,0,,,,,,,,[],,,,
1027531316433219584,1027531316433219584,2018-08-09 17:55:31 IST,2018-08-09,17:55:31,+0530,102754598,johncendpts,John Carroll,,$BIIB (cue ominous music) Biogen‚Äôs high-stakes Alzheimer‚Äôs gamble is being roasted by the experts. Is the amyloid beta theory dead?  https://t.co/knBwVyLuJQ,en,[],['https://endpts.com/biogens-high-stakes-alzheimers-gamble-is-being-roasted-by-the-experts-is-the-amyloid-beta-theory-dead/'],[],2,11,18,[],['biib'],https://twitter.com/JohnCendpts/status/1027531316433219584,False,,0,,,,,,,,[],,,,
1024026818070958083,1024026818070958083,2018-07-31 01:49:53 IST,2018-07-31,01:49:53,+0530,13171622,pharmalot,pharmalot,,Former Biogen sales rep claims she was fired for complaining about an off-label prescribing episode.. read her lawsuit here..  https://t.co/ffhTDRo9Xz #pharma $BIIB,en,[],['https://www.statnews.com/pharmalot/2018/07/30/biogen-sales-rep-lawsuit/'],[],0,3,5,['pharma'],['biib'],https://twitter.com/pharmalot/status/1024026818070958083,False,,0,,,,,,,,[],,,,
1023881717935943681,1023881717935943681,2018-07-30 16:13:19 IST,2018-07-30,16:13:19,+0530,3044635221,maxjacobsedison,"Maxim Jacobs, CFA",,"Ep. 5 (""Biogen gets naughty') of our @ArmchairHealth podcast is out!  Here's a ToC: 00:30 $BIIB 10:30  Silly Alzheimer's pipeline programs 14:32 $TSLA and the futility of attacking short sellers 19:05 $GSK, AI and 23 &amp; me 28:12  $GILD management turnover  https://t.co/mPp24ZZZjK",en,"[{'screen_name': 'armchairhealth', 'name': 'armchair healthcare', 'id': '1011718558685032453'}]",['https://armchairhealthcare.simplecast.fm/60409035'],[],1,4,23,[],"['biib', 'tsla', 'gsk', 'gild']",https://twitter.com/MaxJacobsEdison/status/1023881717935943681,False,,0,,,,,,,,[],,,,
1023191467295232000,1023191467295232000,2018-07-28 18:30:30 IST,2018-07-28,18:30:30,+0530,807184478,birdbrayn,Hal Marston  :^\,,A new #Alzheimers drug shows promise in test trials at #Biogen ($BIIB).  #BAN2401 may slow the disease by 30% if taken at early onset. It attacks sticky amyloid tendrils that form destructive brain plaques. The F.D.A. could expedite approval. #dementia #caregivers #ALZ #health  https://t.co/iwKp4zr2Pt,en,[],[],['https://pbs.twimg.com/media/DjMbNwkW4AAGu7P.jpg'],0,1,6,"['alzheimers', 'biogen', 'ban2401', 'dementia', 'caregivers', 'alz', 'health']",[],https://twitter.com/BirdBrayn/status/1023191467295232000,False,,1,https://pbs.twimg.com/media/DjMbNwkW4AAGu7P.jpg,,,,,,,[],,,,
1022957237285920768,1022957237285920768,2018-07-28 02:59:45 IST,2018-07-28,02:59:45,+0530,3044635221,maxjacobsedison,"Maxim Jacobs, CFA",,"Stay tuned Monday when ep. 5 (""Biogen gets naughty"") of our @armchairhealth podcast is released.  We talk about the $BIIB data, silly things in the  pipeline for Alzheimer's, $GSK buying data from @23andMe as well as both  the $GILD CEO and Chair leaving.  https://t.co/omwqOeJRs0",en,"[{'screen_name': 'armchairhealth', 'name': 'armchair healthcare', 'id': '1011718558685032453'}, {'screen_name': '23andme', 'name': '23andme', 'id': '14738561'}]",['https://armchairhealthcare.simplecast.fm/'],[],0,2,11,[],"['biib', 'gsk', 'gild']",https://twitter.com/MaxJacobsEdison/status/1022957237285920768,False,,0,,,,,,,,[],,,,
1022444660269215745,1022444660269215745,2018-07-26 17:02:57 IST,2018-07-26,17:02:57,+0530,59485976,psk2329,PSK2329 - JHC,,"$BIIB pt raised to $483 from $371 at Citi analyst Robyn Karnauskas after Eisai presented the Phase 2 data for BAN2401. Biogen has three shots to own a piece of Alzheimer's, Karnauskas. The data increases the analyst's confidence in BAN2401 and ""provides positive read through""",en,[],[],[],0,1,6,[],['biib'],https://twitter.com/psk2329/status/1022444660269215745,False,,0,,,,,,,,[],,,,
1022217753946738688,1022217753946738688,2018-07-26 02:01:19 IST,2018-07-26,02:01:19,+0530,26574283,cnbcnow,CNBC Now,,"Biogen and Eisai say Alzheimer‚Äôs treatment slowed disease progression, backing amyloid plaque theory; $BIIB shares volatile after-hours  https://t.co/zrKwF9XdYP  https://t.co/YzyzO2iqW6",en,[],['https://cnb.cx/2v751ML'],['https://pbs.twimg.com/media/Di-lnpAW4AETYvY.png'],2,20,29,[],['biib'],https://twitter.com/CNBCnow/status/1022217753946738688,False,,1,https://pbs.twimg.com/media/Di-lnpAW4AETYvY.png,,,,,,,[],,,,
1022216550877732866,1022216550877732866,2018-07-26 01:56:32 IST,2018-07-26,01:56:32,+0530,801116888,cfromhertz,Christian Fromhertz,,"*BIOGEN, EISAI'S BAN2401 SLOWED ALZHEIMER'S PROGRESSION BY 30% $BIIB",de,[],[],[],2,4,10,[],['biib'],https://twitter.com/cfromhertz/status/1022216550877732866,False,,0,,,,,,,,[],,,,
1022216296631599106,1022216296631599106,2018-07-26 01:55:31 IST,2018-07-26,01:55:31,+0530,102754598,johncendpts,John Carroll,,"BREAKING -- Eisai, Biogen outline an impressive 30% and 47% advantage for their Alzheimer‚Äôs drug BAN2401 $BIIB  https://t.co/axi5imAwYZ",en,[],['https://endpts.com/eisai-biogen-outline-an-impressive-30-and-47-advantage-for-their-alzheimers-drug-ban2401/'],[],1,18,34,[],['biib'],https://twitter.com/JohnCendpts/status/1022216296631599106,False,,0,,,,,,,,[],,,,
1022096437784596485,1022096437784596485,2018-07-25 17:59:15 IST,2018-07-25,17:59:15,+0530,3426014292,semodough,dough,,$BIIB today 430ET  https://t.co/kpvRKuZ6R8 600pm follow up  https://t.co/P5x76ZcW2n Eisai is webcasting the presentation here at 4:30 p.m. ET and Biogen will be holding a follow up webcast at 6 p.m. here.,en,[],"['https://edge.media-server.com/m6/p/ajpiv8im', 'https://edge.media-server.com/m6/p/b5cmdvh8']",[],1,2,9,[],['biib'],https://twitter.com/semodough/status/1022096437784596485,False,,0,,,,,,,,[],,,,
1021931523740786696,1021931523740786696,2018-07-25 07:03:56 IST,2018-07-25,07:03:56,+0530,6810242,bydavidcrow,David Crow,,"Brian Skorney of Baird is not drinking the Biogen/Eisai kool-aid: ‚ÄúThe enthusiasm for a statistically unsound analysis of a failed Phase 2 study that utilizes a company-designed endpoint meant to detect negligible clinical effects is palpable but, in our view, misplaced.‚Äù $BIIB@",en,[],[],[],3,19,46,[],['biib'],https://twitter.com/bydavidcrow/status/1021931523740786696,False,,0,,,,,,,,[],,,,
1021879360142434304,1021879360142434304,2018-07-25 03:36:39 IST,2018-07-25,03:36:39,+0530,253168011,marknewtoncmt,Mark Newton,,"$BIIB Biogen Inc- Most #Healthcare continue to look more appealing than Fincls, or Tech-  #IBDPartner @Marketsmith shows BIIB breaking out to new highs of the year on above-avg volume &amp; could allow for the start of further strength to test 2015 highs @IBDinvestors $XLV  https://t.co/eb950XdBdY",en,"[{'screen_name': 'marketsmith', 'name': 'marketsmith', 'id': '272125054'}, {'screen_name': 'ibdinvestors', 'name': 'investors.com', 'id': '21328656'}]",[],['https://pbs.twimg.com/media/Di5x2jrWwAEjnaR.jpg'],2,1,10,"['healthcare', 'ibdpartner']","['biib', 'xlv']",https://twitter.com/MarkNewtonCMT/status/1021879360142434304,False,,1,https://pbs.twimg.com/media/Di5x2jrWwAEjnaR.jpg,,,,,,,[],,,,
1021870315801124864,1021870315801124864,2018-07-25 03:00:43 IST,2018-07-25,03:00:43,+0530,44366481,hulkcapital,HULKüëä,,"JPMorgan expects 'FOMO' trading for Biogen, ups price target to $445 $BIIB",en,[],[],[],2,3,11,[],['biib'],https://twitter.com/HulkCapital/status/1021870315801124864,False,,0,,,,,,,,[],,,,
1021848170450612225,1021848170450612225,2018-07-25 01:32:43 IST,2018-07-25,01:32:43,+0530,61342056,optionshawk,Joe Kunkle,,"Biogen $BIIB buyer of 1,000 August $410/$425 call spreads for $2.70 right before the bell into Alzheimer‚Äôs presentation",en,[],[],[],0,7,18,[],['biib'],https://twitter.com/OptionsHawk/status/1021848170450612225,False,,0,,,,,,,,[],,,,
1021832955508019207,1021832955508019207,2018-07-25 00:32:15 IST,2018-07-25,00:32:15,+0530,41579206,eddieblanco,Eddie Blanco,,Buy #BIOGEN (BIIB) #STOCK it‚Äôs gonna jump 30% tomorrow HURRY ASAP  https://t.co/Gky0dQDkCn,en,[],[],['https://pbs.twimg.com/media/Di5Hp2-W0AElQ8k.jpg'],0,7,9,"['biogen', 'stock']",[],https://twitter.com/EddieBlanco/status/1021832955508019207,False,,1,https://pbs.twimg.com/media/Di5Hp2-W0AElQ8k.jpg,,,,,,,[],,,,
1021764313571184641,1021764313571184641,2018-07-24 19:59:30 IST,2018-07-24,19:59:30,+0530,21328656,ibdinvestors,Investors.com,,"Alphabet earnings fuel all-time high for Nasdaq; Biogen soars on earnings, outlook $GOOGL $BIIB $FB $TXN  https://t.co/quDbGiY3gs",en,[],['https://www.pscp.tv/w/bicvSjFkclFla1dEZU5namJ8MURYR3lZWlJxRG5HTWai_f54sf1svCcSfe9PCs9pmx6sJ8awMQ1Pje3c-Tmr'],[],0,4,9,[],"['googl', 'biib', 'fb', 'txn']",https://twitter.com/IBDinvestors/status/1021764313571184641,False,,0,,,,,,,,[],,,,
1021723985728417792,1021723985728417792,2018-07-24 17:19:15 IST,2018-07-24,17:19:15,+0530,3426014292,semodough,dough,,LR Wild Ride Ahead... AAIC '2401 Data Could Drive ~$20 Down or ~$40 Up ‚Ä¢ Bottom Line: Biogen‚Äôs stock faces tremendous volatility around the presentation of BAN2401 data at Alzheimer's Association International Conference (AAIC) meeting $BIIB,en,[],[],[],0,2,7,[],['biib'],https://twitter.com/semodough/status/1021723985728417792,False,,0,,,,,,,,[],,,,
1021718771721953281,1021718771721953281,2018-07-24 16:58:32 IST,2018-07-24,16:58:32,+0530,849093025884237825,sanctuary_bio,Wilson Cheung,,$BIIB worth noting they bought back 2.75B shares at avg 286/share...sizable amount for company this size in a single q  Hopes for any late-stage/commercial M&amp;A from Biogen rly going down the drain.,en,[],[],[],3,1,10,[],['biib'],https://twitter.com/Sanctuary_Bio/status/1021718771721953281,False,,0,,,,,,,,[],,,,
1021486923175604224,1021486923175604224,2018-07-24 01:37:15 IST,2018-07-24,01:37:15,+0530,16827489,cboe,Cboe,,Trader Sells Puts in Biogen $BIIB @RussellRhoads   https://t.co/U9MapdxSKw,de,"[{'screen_name': 'russellrhoads', 'name': 'russell rhoads', 'id': '23193379'}]",['https://www.youtube.com/watch?v=2cpRpO4AG-s'],[],0,3,8,[],['biib'],https://twitter.com/CBOE/status/1021486923175604224,False,,0,,,,,,,,[],,,,
1019547470592921600,1019547470592921600,2018-07-18 17:10:33 IST,2018-07-18,17:10:33,+0530,61342056,optionshawk,Joe Kunkle,,"$BIIB ‚Äì July 27th (W) $350 Call OI to 3,255 from 1,261 - Alzheimer's Association International Conference (AAIC) in Chicago (July 22-26) - Biogen also reports 7/24, so a big week",en,[],[],[],1,3,15,[],['biib'],https://twitter.com/OptionsHawk/status/1019547470592921600,False,,0,,,,,,,,[],,,,
1017382737643126789,1017382737643126789,2018-07-12 17:48:41 IST,2018-07-12,17:48:41,+0530,849093025884237825,sanctuary_bio,Wilson Cheung,,"$BIIB Oi, @biogen, if you don't want to spend over $10B on $SRPT $SAGE or $NBIX, the EV of $ZGNX under $2B just fyi. No need to thank me  Or bet it all on aducanumab and 2401, what could possibly go wrong.",en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],[],0,1,12,[],"['biib', 'srpt', 'sage', 'nbix', 'zgnx']",https://twitter.com/Sanctuary_Bio/status/1017382737643126789,False,,0,,,,,,,,[],,,,
1015616401363652608,1015616401363652608,2018-07-07 20:49:53 IST,2018-07-07,20:49:53,+0530,104257356,briansozzi,Brian Sozzi,,The Biogen blowout cc: @jimcramer  https://t.co/tQ1mWoaenh $BIIB,ht,"[{'screen_name': 'jimcramer', 'name': 'jim cramer', 'id': '14216123'}]",['https://bit.ly/2uc3R1Z'],[],0,8,11,[],['biib'],https://twitter.com/BrianSozzi/status/1015616401363652608,False,,0,,,,,,,,[],,,,
1015209198722961408,1015209198722961408,2018-07-06 17:51:49 IST,2018-07-06,17:51:49,+0530,2334614718,openoutcrier,Open Outcrier,,$BIIB (+13.1% pre) Biogen Surges After Positive Results in Alzheimer‚Äôs Trial - BBG   https://t.co/ll36IdEDB8,en,[],['http://ooc.bz/l/25173'],[],0,3,6,[],['biib'],https://twitter.com/OpenOutcrier/status/1015209198722961408,False,,0,,,,,,,,[],,,,
1015203493186023424,1015203493186023424,2018-07-06 17:29:09 IST,2018-07-06,17:29:09,+0530,44438256,matthewherper,Matthew Herper,,"Geoff Porges from Leerink on $BIIB/ Eisai data:  ""We do not feel that Biogen, Eisai or the whole amyloid field deserves much credit for this disclosure, particularly given the lack of external validation of the ADCOMS endpoint.""",en,[],[],[],0,2,12,[],['biib'],https://twitter.com/matthewherper/status/1015203493186023424,False,,0,,,,,,,,[],,,,
1015201399280369664,1015201399280369664,2018-07-06 17:20:49 IST,2018-07-06,17:20:49,+0530,14292717,petenajarian,Pete Najarian,,"This is huge, ‚ÄúBiogen is declaring success‚Äù $BIIB, reaction early reflected with 13% move higher!  https://t.co/0yS5FlXhWN",en,[],['https://twitter.com/statnews/status/1015015383609339904'],[],9,15,50,[],['biib'],https://twitter.com/petenajarian/status/1015201399280369664,False,https://twitter.com/statnews/status/1015015383609339904,0,,,,,,,,[],,,,
1015026365991669762,1015026365991669762,2018-07-06 05:45:18 IST,2018-07-06,05:45:18,+0530,44438256,matthewherper,Matthew Herper,,"Biogen And Eisai Say Alzheimer's Drug A Success, Reversing Earlier Result $BIIB  https://t.co/kOVex0HlGd",en,[],['https://www.forbes.com/sites/matthewherper/2018/07/05/biogen-and-eisai-say-alzheimers-drug-a-success-reversing-earlier-result/#53e129a328b4'],[],0,9,25,[],['biib'],https://twitter.com/matthewherper/status/1015026365991669762,False,,0,,,,,,,,[],,,,
1009084441866596352,1009084441866596352,2018-06-19 20:14:13 IST,2018-06-19,20:14:13,+0530,849093025884237825,sanctuary_bio,Wilson Cheung,,"$SRPT this data solidifies SRPT's place among SMid dominance  I coin $SRPT $NBIX $SAGE the CNS Holy Trifecta  Poor $BIIB, those premiums really gonna cost you now @biogen",en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],[],0,2,16,[],"['srpt', 'srpt', 'nbix', 'sage', 'biib']",https://twitter.com/Sanctuary_Bio/status/1009084441866596352,False,,0,,,,,,,,[],,,,
1004802938185760768,1004802938185760768,2018-06-08 00:41:03 IST,2018-06-08,00:41:03,+0530,223589965,gantosj,Joe,,"Just think about it for a moment, why would Dr. O'Neill move from $BIIB to $SRT ?? He must saw a promising #GeneTherapy franchise that can grow the company to a higher levels to make him move from Biogen (X10 of SRPT Mcap) to Sarepta.. that's very positive IMO  https://t.co/JLB6B42f3v",en,[],['https://twitter.com/GantosJ/status/1004703192658030593'],[],2,1,11,['genetherapy'],"['biib', 'srt']",https://twitter.com/GantosJ/status/1004802938185760768,False,https://twitter.com/GantosJ/status/1004703192658030593,0,,,,,,,,[],,,,
1001892006585622529,1001892006585622529,2018-05-30 23:54:03 IST,2018-05-30,23:54:03,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"at Bernstein Michel Vounatsos - $BIIB Biogen Inc. - CEO &amp; Director says ""we are watching also very carefully #gene #editing, a very stimulating space "" please not that $BIIB had coloborations with $SGMO before , before these programs were spun out to $BIVV now $SNY  https://t.co/z2FuNWPFpt",en,[],[],['https://pbs.twimg.com/media/DedvbqqXcAA-2PB.jpg'],1,6,5,"['gene', 'editing']","['biib', 'biib', 'sgmo', 'bivv', 'sny']",https://twitter.com/_B_I_O_T_E_C_H_/status/1001892006585622529,False,,1,https://pbs.twimg.com/media/DedvbqqXcAA-2PB.jpg,,,,,,,[],,,,
997995064403152896,997995064403152896,2018-05-20 05:48:59 IST,2018-05-20,05:48:59,+0530,466333756,seeitmarket,See It Market,,Biogen (BIIB): Using Options to Position for a Move Higher -  https://t.co/uB58gOniIK  blog by @MitchellKWarren  $BIIB $IBB,da,"[{'screen_name': 'mitchellkwarren', 'name': 'mitchell warren', 'id': '34741114'}]",['https://www.seeitmarket.com/biogen-biib-using-options-position-for-move-higher-17968/#.WwC-pLMXXbk.twitter'],[],0,3,7,[],"['biib', 'ibb']",https://twitter.com/seeitmarket/status/997995064403152896,False,,0,,,,,,,,[],,,,
996174489212899329,996174489212899329,2018-05-15 05:14:40 IST,2018-05-15,05:14:40,+0530,34741114,mitchellkwarren,Mitchell Warren,,Biogen (BIIB): Using Options to Position for a Move Higher  https://t.co/icosInqRoV my new post via @seeitmarket $BIIB  https://t.co/gboX8n6FvA,en,"[{'screen_name': 'seeitmarket', 'name': 'see it market', 'id': '466333756'}]",['https://www.seeitmarket.com/biogen-biib-using-options-position-for-move-higher-17968/'],"['https://pbs.twimg.com/media/DdMfI3pXkAAFk09.jpg', 'https://pbs.twimg.com/media/DdMfMpyWAAAAG3F.jpg']",0,6,11,[],['biib'],https://twitter.com/MitchellKWarren/status/996174489212899329,False,,1,https://pbs.twimg.com/media/DdMfI3pXkAAFk09.jpg,,,,,,,[],,,,
994931401320550401,994931401320550401,2018-05-11 18:55:05 IST,2018-05-11,18:55:05,+0530,82095703,cbtadvisors,Steven Dickman,,"A highlight at #CVForum18 today: Phil Sharp of @MIT on the founding &amp; early years of @Biogen $BIIB. Schering Plough invested $10M on top of the $1M #VC seed investment. In exchange, SGP got options on 3 products out of a list incl. a-interferon, hep B vaccine &amp; human insulin.",en,"[{'screen_name': 'mit', 'name': 'massachusetts institute of technology (mit)', 'id': '15460048'}, {'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],[],2,3,6,"['cvforum18', 'vc']",['biib'],https://twitter.com/cbtadvisors/status/994931401320550401,False,,0,,,,,,,,[],,,,
994930427633823747,994930427633823747,2018-05-11 18:51:13 IST,2018-05-11,18:51:13,+0530,47348249,michael_gilman,Michael Gilman,,Deborah Dunsire: ‚ÄúDid Wally Gilbert‚Äôs 1980 Nobel help Biogen‚Äôs development?‚Äù  Phil Sharp: ‚ÄúIt didn‚Äôt hurt.‚Äù  Fun #CVForum18 session on $BIIB history.,en,[],[],[],0,3,8,['cvforum18'],['biib'],https://twitter.com/michael_gilman/status/994930427633823747,False,,0,,,,,,,,[],,,,
987300043383336961,987300043383336961,2018-04-20 17:30:48 IST,2018-04-20,17:30:48,+0530,632341632,andybiotech,Andy Biotech,,"$BIIB $IONS Interesting slide on antisense and gene therapy being ""Complementary"", ""Combination / sequential"".  Will see if Biogen answer any question re $AVXS  https://t.co/Sf980qAhKw",en,[],[],['https://pbs.twimg.com/media/DbOYABuXkAIbOaw.jpg'],1,10,17,[],"['biib', 'ions', 'avxs']",https://twitter.com/AndyBiotech/status/987300043383336961,False,,1,https://pbs.twimg.com/media/DbOYABuXkAIbOaw.jpg,,,,,,,[],,,,
987277271349293056,987277271349293056,2018-04-20 16:00:18 IST,2018-04-20,16:00:18,+0530,102754598,johncendpts,John Carroll,,Biogen pays $1B cash to enlist Ionis on a new drug discovery campaign ‚Äî but can it deliver fast enough for analysts? $BIIB $IONS  https://t.co/25Bt8QVaV4,en,[],['https://endpts.com/biogen-pays-1b-cash-to-enlist-ionis-on-a-new-drug-discovery-campaign-but-can-it-deliver-fast-enough-for-analysts/'],[],3,15,25,[],"['biib', 'ions']",https://twitter.com/JohnCendpts/status/987277271349293056,False,,0,,,,,,,,[],,,,
984018220364550145,984018220364550145,2018-04-11 16:10:00 IST,2018-04-11,16:10:00,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$BIIB and the badly needed gene therapy acquisition that got away  https://t.co/SibSJoYDV6 I speak of $AVXS, of course.  Tick tock, Biogen...",en,[],['https://www.statnews.com/2018/04/11/biogen-gene-therapy-acquisition/'],[],7,6,8,[],"['biib', 'avxs']",https://twitter.com/adamfeuerstein/status/984018220364550145,False,,0,,,,,,,,[],,,,
981867636794458112,981867636794458112,2018-04-05 17:44:21 IST,2018-04-05,17:44:21,+0530,632341632,andybiotech,Andy Biotech,,"$ABBV $BIIB Settlement on Humira #Biosimilar in Europe --&gt; Biogen expects to launch IMRALDI in Europe on October 16, 2018  AbbVie will grant patent licenses on a country-by-country basis, and receives royalty payments  CC @biosimilarz @ZacharyBrennan",en,"[{'screen_name': 'biosimilarz', 'name': 'biosimilarz', 'id': '239982538'}, {'screen_name': 'zacharybrennan', 'name': 'zach brennan', 'id': '605657704'}]",[],[],2,10,14,['biosimilar'],"['abbv', 'biib']",https://twitter.com/AndyBiotech/status/981867636794458112,False,,0,,,,,,,,[],,,,
964437462893453312,964437462893453312,2018-02-16 15:23:04 IST,2018-02-16,15:23:04,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,#genome #editing to #cure #HIV #infection (Using $SGMO Zinc finger)  @GileadSciences @abbvie @pfizer @bmsnews @Celgene @NovartisScience @VasNarasimhan @Amgen @biogen @sanofi @Roche  $GILD $ABBV $PFE $BMY $CELG $NVS $AMGN $BIIB $SNY $RHHBY   https://t.co/irVjPxJyJJ,en,"[{'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'bmsnews', 'name': 'bristol myers squibb', 'id': '34010976'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'novartisscience', 'name': 'novartis science', 'id': '2260514101'}, {'screen_name': 'vasnarasimhan', 'name': 'vas narasimhan', 'id': '723488741348782080'}, {'screen_name': 'amgen', 'name': 'amgen', 'id': '28436760'}, {'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'sanofi', 'name': 'sanofi', 'id': '35846368'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}]",['https://www.youtube.com/watch?v=WPp-ip0Nwyk'],[],1,4,7,"['genome', 'editing', 'cure', 'hiv', 'infection']","['sgmo', 'gild', 'abbv', 'pfe', 'bmy', 'celg', 'nvs', 'amgn', 'biib', 'sny', 'rhhby']",https://twitter.com/Biotech2050/status/964437462893453312,False,,0,,,,,,,,[],,,,
960983975216009217,960983975216009217,2018-02-07 02:40:08 IST,2018-02-07,02:40:08,+0530,61342056,optionshawk,Joe Kunkle,,"Biogen $BIIB with 1,000 Feb. 23rd (W) $340 calls bought to open $6 to $6.50 late day",en,[],[],[],1,6,22,[],['biib'],https://twitter.com/OptionsHawk/status/960983975216009217,False,,0,,,,,,,,[],,,,
956516536352755712,956516536352755712,2018-01-25 18:48:08 IST,2018-01-25,18:48:08,+0530,229246832,lifescivc,Bruce Booth,,"Biogen's $KPTI license deal this morning is a rounding error for $BIIB.  Its $10M, not $210M. Literally a small fraction of the interest they will make on their $3.5B in cash sitting in a savings account this year.",en,[],[],[],1,4,7,[],"['kpti', 'biib']",https://twitter.com/LifeSciVC/status/956516536352755712,False,,0,,,,,,,,[],,,,
956507327162716160,956507327162716160,2018-01-25 18:11:32 IST,2018-01-25,18:11:32,+0530,102754598,johncendpts,John Carroll,,"Biogen makes a buyout deal, but it‚Äôs not the big one you‚Äôve been waiting for $BIIB $KPTI  https://t.co/nh05PluOMQ",en,[],['https://endpts.com/biogen-makes-a-buyout-deal-but-its-not-the-big-one-youve-been-waiting-for/'],[],2,5,6,[],"['biib', 'kpti']",https://twitter.com/JohnCendpts/status/956507327162716160,False,,0,,,,,,,,[],,,,
954345197592371201,954345197592371201,2018-01-19 19:00:00 IST,2018-01-19,19:00:00,+0530,2334614718,openoutcrier,Open Outcrier,,$ACOR (+14.8% pre) Acorda shares jump premarket on talk of possible takeover by Biogen $BIIB other suitors - MW   https://t.co/I8E6wGyZxf,en,[],['http://ooc.bz/l/19842'],[],0,2,4,[],"['acor', 'biib']",https://twitter.com/OpenOutcrier/status/954345197592371201,False,,0,,,,,,,,[],,,,
950074974110281728,950074974110281728,2018-01-08 00:11:40 IST,2018-01-08,00:11:40,+0530,370238655,jodigralnick,jodi gralnick,,"#JPM18 starts tomorrow and @CNBCnow has you covered! @megtirrell LIVE w/ CEOs of $BIIB $LLY $GSK $EDIT $MRK $ILMN $JNJ $FOLD $GILD $REGN Monday &amp; Tuesday, plus more, starting @SquawkCNBC tomorrow 830amET w @biogen EXCLUSIVE.  https://t.co/1PUx61GQKF",en,"[{'screen_name': 'cnbcnow', 'name': 'cnbc now', 'id': '26574283'}, {'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}, {'screen_name': 'squawkcnbc', 'name': 'squawk box', 'id': '404422077'}, {'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],['https://pbs.twimg.com/media/DS9YJifUMAAqIdr.jpg'],0,28,24,['jpm18'],"['biib', 'lly', 'gsk', 'edit', 'mrk', 'ilmn', 'jnj', 'fold', 'gild', 'regn']",https://twitter.com/jodigralnick/status/950074974110281728,False,,1,https://pbs.twimg.com/media/DS9YJifUMAAqIdr.jpg,,,,,,,[],,,,
949278061803003905,949278061803003905,2018-01-05 19:25:01 IST,2018-01-05,19:25:01,+0530,298953617,techcharts,"Aksel Kibar, CMT",,$BIIB #BIOGEN possibly completed another short-term sideways consolidation. Getting ready to resume uptrend. Old resistance becomes support. $qqq  https://t.co/mt1VV9sNyv,en,[],[],['https://pbs.twimg.com/media/DSyDXbqWsAEsfxQ.jpg'],0,2,8,['biogen'],"['biib', 'qqq']",https://twitter.com/TechCharts/status/949278061803003905,False,,1,https://pbs.twimg.com/media/DSyDXbqWsAEsfxQ.jpg,,,,,,,[],,,,
943841915191078912,943841915191078912,2017-12-21 19:23:42 IST,2017-12-21,19:23:42,+0530,102754598,johncendpts,John Carroll,,"Looking for an early success in PhII Alzheimer‚Äôs study, Biogen and Eisai just racked up the latest setback $BIIB  https://t.co/57DKnQqxpe",en,[],['https://endpts.com/looking-for-an-early-success-in-phii-alzheimers-study-biogen-and-eisai-just-racked-up-the-latest-setback/'],[],0,13,7,[],['biib'],https://twitter.com/JohnCendpts/status/943841915191078912,False,,0,,,,,,,,[],,,,
939566878095282178,818574597993828352,2017-12-10 00:16:14 IST,2017-12-10,00:16:14,+0530,146342882,pakbenikasim,üÖüüÖêüÖö,,"Actualizaci√≥n:  Gilead $GILD Mylan $MYL Biogen $BIIB Perrigo $PRGO  Tanto Gilead como Biogen se movieron al alza y est√°n para iniciar un nuevo impulso, pero Perrigo y Mylan siguen en un punto muy similar trabajando el comienzo alcista  #bolsa  https://t.co/UNuLWooqrL",es,[],[],"['https://pbs.twimg.com/media/DQoC_phW4AATHp6.jpg', 'https://pbs.twimg.com/media/DQoC_pIWkAA3mOQ.jpg', 'https://pbs.twimg.com/media/DQoC_pyW4AIR5Wv.jpg', 'https://pbs.twimg.com/media/DQoC_puXkAAHuKt.jpg']",0,3,14,['bolsa'],"['gild', 'myl', 'biib', 'prgo']",https://twitter.com/PakBenikasim/status/939566878095282178,False,,1,https://pbs.twimg.com/media/DQoC_phW4AATHp6.jpg,,,,,,,[],,,,
938850429290631168,938850429290631168,2017-12-08 00:49:19 IST,2017-12-08,00:49:19,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"Bernstein: Acquisitions and in-licensing is a must ... list of monogenic #CNS diseases that look of interest to $BIIB Biogen, but these too could of interest to UCB : Sangamo $SGMO .... ... In short, at the top end, a ‚Ç¨4-5B #deal is feasible  https://t.co/qThga9C5kc",en,[],[],['https://pbs.twimg.com/media/DQd3e-BW0AAsHvV.jpg'],0,5,8,"['cns', 'deal']","['biib', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/938850429290631168,False,,1,https://pbs.twimg.com/media/DQd3e-BW0AAsHvV.jpg,,,,,,,[],,,,
912633117168607233,912633117168607233,2017-09-26 16:31:05 IST,2017-09-26,16:31:05,+0530,61342056,optionshawk,Joe Kunkle,,$BIIB - Biogen Last Man Standing  https://t.co/zwzBZBRmTk,ht,[],['https://twitter.com/BioStocks/status/912633036554014720'],[],1,0,10,[],['biib'],https://twitter.com/OptionsHawk/status/912633117168607233,False,https://twitter.com/BioStocks/status/912633036554014720,0,,,,,,,,[],,,,
906248267897466881,906248267897466881,2017-09-09 01:39:59 IST,2017-09-09,01:39:59,+0530,61342056,optionshawk,Joe Kunkle,,"Biogen $BIIB Sep. 22nd (W) $340 calls bought to open 1,000X 10 minutes before the close $2.90 to $3.50",en,[],[],[],1,9,23,[],['biib'],https://twitter.com/OptionsHawk/status/906248267897466881,False,,0,,,,,,,,[],,,,
902943587054354432,902943056667791360,2017-08-30 22:48:21 IST,2017-08-30,22:48:21,+0530,298953617,techcharts,"Aksel Kibar, CMT",,A great chart set up we are following on the #TECHCHARTSWATCHLIST is #BIOGEN $BIIB #NASDAQ $QQQ &gt;&gt;  https://t.co/3PXD6BGq77  https://t.co/weLskNfkvx,en,[],['http://blog.techcharts.net'],['https://pbs.twimg.com/media/DIfmWgPXkAAN-oP.jpg'],1,3,9,"['techchartswatchlist', 'biogen', 'nasdaq']","['biib', 'qqq']",https://twitter.com/TechCharts/status/902943587054354432,False,,1,https://pbs.twimg.com/media/DIfmWgPXkAAN-oP.jpg,,,,,,,[],,,,
889795779040301056,889795779040301056,2017-07-25 16:03:39 IST,2017-07-25,16:03:39,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$BIIB SAYS THROUGH END OF DECADE, BIOGEN EXPECTS CASH FLOWS TO ""SIGNIFICANTLY INCREASE""",en,[],[],[],1,0,5,[],['biib'],https://twitter.com/_B_I_O_T_E_C_H_/status/889795779040301056,False,,0,,,,,,,,[],,,,
879433725804720128,879433725804720128,2017-06-27 01:48:33 IST,2017-06-27,01:48:33,+0530,1069486704,wolfmetric,Wolfmetric,,"Biogen $BIIB today with 500 July 28th (W) $285/$300 call spreads bought against a sale of the $260 puts, net debit of $0.45",en,[],[],[],0,1,5,[],['biib'],https://twitter.com/Wolfmetric/status/879433725804720128,False,,0,,,,,,,,[],,,,
856969882818273280,856969882818273280,2017-04-26 02:05:16 IST,2017-04-26,02:05:16,+0530,132613598,donibloomfield,Doni Bloomfield,,"Yet again, Biogen US Tecfidera sales rely on price increases for growth, as volume falls 7%. But they're also giving higher discounts $BIIB  https://t.co/fegLdzUDVP",en,[],[],['https://pbs.twimg.com/media/C-SRdl6XkAAlWJj.jpg'],2,13,9,[],['biib'],https://twitter.com/DoniBloomfield/status/856969882818273280,False,,1,https://pbs.twimg.com/media/C-SRdl6XkAAlWJj.jpg,,,,,,,[],,,,
840926079829364736,840926079829364736,2017-03-12 19:32:55 IST,2017-03-12,19:32:55,+0530,298953617,techcharts,"Aksel Kibar, CMT",,$QQQ #NASDAQ $BIIB BIOGEN forms 6 month-long symm triangle. A daily close above 307 will confirm the breakout. #TECHCHARTSWATCHLIST  https://t.co/B0uII6hJfl,en,[],[],['https://pbs.twimg.com/media/C6uRy3qWYAAdKgZ.jpg'],0,4,13,"['nasdaq', 'techchartswatchlist']","['qqq', 'biib']",https://twitter.com/TechCharts/status/840926079829364736,False,,1,https://pbs.twimg.com/media/C6uRy3qWYAAdKgZ.jpg,,,,,,,[],,,,
823567092892872706,823567092892872706,2017-01-23 21:54:30 IST,2017-01-23,21:54:30,+0530,102527566,biorunup,BioRunUp,,$BIIB 5 Reasons Celgene Should Buy Biogen - by @adamfeuerstein  https://t.co/MBUL1UMic8 $CELG,et,"[{'screen_name': 'adamfeuerstein', 'name': 'adam feuerstein', 'id': '102094857'}]",['http://realmoney.thestreet.com/articles/01/23/2017/5-reasons-celgene-should-buy-biogen'],[],0,3,6,[],"['biib', 'celg']",https://twitter.com/BioRunUp/status/823567092892872706,False,,0,,,,,,,,[],,,,
821823058608607232,821823058608607232,2017-01-19 02:24:20 IST,2017-01-19,02:24:20,+0530,106542267,cenmag,C&EN,,Biogen pays $1.25 billion to protect a blockbuster drug  https://t.co/cLjo4MW7dF $BIIB  https://t.co/ron9d58soc,en,[],['http://ow.ly/irul3088mky'],['https://pbs.twimg.com/media/C2eztvlWEAIIBW2.jpg'],0,4,9,[],['biib'],https://twitter.com/cenmag/status/821823058608607232,False,,1,https://pbs.twimg.com/media/C2eztvlWEAIIBW2.jpg,,,,,,,[],,,,
821409634237825025,821409634237825025,2017-01-17 23:01:32 IST,2017-01-17,23:01:32,+0530,31546412,tradehawk,TradeHawk,,"$SNSS $BIIB fwiw interesting complaint, Sunesis Pharmaceuticals sues Biogen over BTK collaboration.  https://t.co/cesuCxdCHG",en,[],['https://www.scribd.com/document/336806720/Sunesis-Pharmaceuticals-vs-Biogen-Complaint'],[],0,1,4,[],"['snss', 'biib']",https://twitter.com/TradeHawk/status/821409634237825025,False,,0,,,,,,,,[],,,,
816260596182224896,816260596182224896,2017-01-03 18:01:06 IST,2017-01-03,18:01:06,+0530,3043828834,cgrantwsj,Charley Grant,,Biogen's old CEO went out of his way to slam Martin Shkreli for relying on price hikes to do business. $BIIB  https://t.co/L56ZVKX8dI,en,[],['https://twitter.com/megtirrell/status/816260312416579584'],[],3,6,25,[],['biib'],https://twitter.com/CGrantWSJ/status/816260596182224896,False,https://twitter.com/megtirrell/status/816260312416579584,0,,,,,,,,[],,,,
814589901303848960,814589901303848960,2016-12-30 03:22:21 IST,2016-12-30,03:22:21,+0530,102754598,johncendpts,John Carroll,,New drug price controversy looms as Biogen stuns payers with Spinraza‚Äôs $750K sticker ‚Äî analyst $BIIB $IONS  https://t.co/lGYAM2l9eI,en,[],['https://endpts.com/new-drug-price-controversy-looms-as-biogen-stuns-payers-with-spinrazas-750k-sticker-analyst/'],[],2,10,9,[],"['biib', 'ions']",https://twitter.com/JohnCendpts/status/814589901303848960,False,,0,,,,,,,,[],,,,
814506268576493568,814506268576493568,2016-12-29 21:50:01 IST,2016-12-29,21:50:01,+0530,112872946,biostocks,Bio Stocks‚Ñ¢,,"$BIIB - $750,000 first-year price of new Biogen drug makes it one of the costliest medicines ever  https://t.co/UMyPQKuVwB #pharma",en,[],['https://www.statnews.com/2016/12/28/biogen-drug-price-costliest/'],[],2,5,7,['pharma'],['biib'],https://twitter.com/BioStocks/status/814506268576493568,False,,0,,,,,,,,[],,,,
813415907712188418,813415907712188418,2016-12-26 21:37:19 IST,2016-12-26,21:37:19,+0530,112872946,biostocks,Bio Stocks‚Ñ¢,,"$BIIB - No matter who the CEO is, Biogen's in trouble  https://t.co/EptnFalYfg #biotech",en,[],['http://www.bloomberg.com/gadfly/articles/2016-12-20/biogen-s-new-ceo-has-a-tough-task'],[],1,5,11,['biotech'],['biib'],https://twitter.com/BioStocks/status/813415907712188418,False,,0,,,,,,,,[],,,,
811208848375742465,811208848375742465,2016-12-20 19:27:15 IST,2016-12-20,19:27:15,+0530,19717430,zbiotech,zach,,hmmm *BIOGEN:WOULD LOOK INTO GETTING INTO OPHTHALMOLOGY SPACE $BIIB,en,[],[],[],1,3,6,[],['biib'],https://twitter.com/zbiotech/status/811208848375742465,False,,0,,,,,,,,[],,,,
806966336878477312,806966336878477312,2016-12-09 02:29:02 IST,2016-12-09,02:29:02,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,$BIIB Biogen aducanumab data from long-term extension; first impressions  https://t.co/Yw6yCJbcjX,en,[],[],"['https://pbs.twimg.com/media/CzLrlkRWEAAFA0n.jpg', 'https://pbs.twimg.com/media/CzLrmSnXcAQwiC_.jpg']",2,15,14,[],['biib'],https://twitter.com/_B_I_O_T_E_C_H_/status/806966336878477312,False,,1,https://pbs.twimg.com/media/CzLrlkRWEAAFA0n.jpg,,,,,,,[],,,,
806963396184834049,806963396184834049,2016-12-09 02:17:20 IST,2016-12-09,02:17:20,+0530,102754598,johncendpts,John Carroll,,Biogen stock jumps after positive efficacy data for aducanumab in Alzheimer‚Äôs is leaked online $BIIB  https://t.co/T5wJmHdUH5,en,[],['https://endpts.com/biogen-stock-jumps-after-positive-efficacy-data-for-aducanumab-in-alzheimers-is-leaked-online/'],[],0,5,5,[],['biib'],https://twitter.com/JohnCendpts/status/806963396184834049,False,,0,,,,,,,,[],,,,
795668823168913409,795668823168913409,2016-11-07 22:16:44 IST,2016-11-07,22:16:44,+0530,234462824,graf_rachel,Rachel Graf,,Leerink upgrades Biogen stock on positive Spinraza trial  https://t.co/ZGVhGS1Ffs $BIIB $IONS @TheStreet,en,"[{'screen_name': 'thestreet', 'name': 'thestreet', 'id': '15281391'}]",['https://www.thestreet.com/story/13882922/2/shares-of-biogen-ionis-gain-on-positive-spinraza-trial.html'],[],0,3,6,[],"['biib', 'ions']",https://twitter.com/graf_rachel/status/795668823168913409,False,,0,,,,,,,,[],,,,
791253894701744128,791253894701744128,2016-10-26 17:53:23 IST,2016-10-26,17:53:23,+0530,2334614718,openoutcrier,Open Outcrier,,$BIIB (+1.4% pre) Biogen profit beats estimates on sales of MS drug - MarketWatch   https://t.co/kpI6edQrgt,en,[],['http://ooc.bz/l/7233'],[],0,4,4,[],['biib'],https://twitter.com/OpenOutcrier/status/791253894701744128,False,,0,,,,,,,,[],,,,
785148373108129792,785148373108129792,2016-10-09 21:32:14 IST,2016-10-09,21:32:14,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$IONS $BIIB $ALNY Thoughts on SMA Data from the WMS Meeting This weekend, Biogen and partner Ionis (covered (cont)  https://t.co/PlI8oY9P7O",en,[],['http://tl.gd/n_1sp6cmh'],[],0,7,9,[],"['ions', 'biib', 'alny']",https://twitter.com/_B_I_O_T_E_C_H_/status/785148373108129792,False,,0,,,,,,,,[],,,,
776510158109286400,776510158109286400,2016-09-16 01:27:03 IST,2016-09-16,01:27:03,+0530,82095703,cbtadvisors,Steven Dickman,,"Biogen $BIIB has placed 9 women on boards via their ""Raising the Bar"" initiative #boardstep16",en,[],[],[],0,1,5,['boardstep16'],['biib'],https://twitter.com/cbtadvisors/status/776510158109286400,False,,0,,,,,,,,[],,,,
771685784562896896,771685784562896896,2016-09-02 17:56:42 IST,2016-09-02,17:56:42,+0530,2334614718,openoutcrier,Open Outcrier,,$BIIB (+1.6% pre) Biogen shares rise after FDA fast-tracks Alzheimer‚Äôs treatment - MarketWatch    https://t.co/txjq36QC1F,en,[],['http://ooc.bz/l/5973'],[],0,2,5,[],['biib'],https://twitter.com/OpenOutcrier/status/771685784562896896,False,,0,,,,,,,,[],,,,
771444761760768000,771444761760768000,2016-09-02 01:58:58 IST,2016-09-02,01:58:58,+0530,61342056,optionshawk,Joe Kunkle,,Biogen $BIIB buyer paid $6.50 to $7.30 for 500 October 14th (W) $330 calls with the recent talk of it being a possible M&amp;A target,en,[],[],[],0,8,13,[],['biib'],https://twitter.com/OptionsHawk/status/771444761760768000,False,,0,,,,,,,,[],,,,
771310613062529024,771310613062529024,2016-09-01 17:05:55 IST,2016-09-01,17:05:55,+0530,102754598,johncendpts,John Carroll,,"This still disturbs me: Biogen hypes a fresh set of early, upbeat results for Alzheimer‚Äôs drug $BIIB  https://t.co/dYdeyyzvjv",en,[],['http://endpts.com/biogen-touts-a-fresh-set-of-early-upbeat-results-for-alzheimers-drug/?utm_medium=email&utm_campaign=Thursday%20%20September%201%202016&utm_content=Thursday%20%20September%201%202016+CID_2635db695cab72d29b881a2082df255e&utm_source=ENDPOINTS%20emails&utm_term=Biogen%20touts%20a%20fresh%20set%20of%20early%20upbeat%20results%20for%20Alzheimers%20drug'],[],5,6,8,[],['biib'],https://twitter.com/JohnCendpts/status/771310613062529024,False,,0,,,,,,,,[],,,,
760904422444699648,760904422444699648,2016-08-03 23:55:25 IST,2016-08-03,23:55:25,+0530,632341632,andybiotech,Andy Biotech,,$BIIB here is the Reuters story  Biogen not pursuing a sale: source  https://t.co/it1dhzD4jo,en,[],['http://www.reuters.com/article/us-biogen-m-a-allergan-idUSKCN10E28M'],[],0,8,6,[],['biib'],https://twitter.com/AndyBiotech/status/760904422444699648,False,,0,,,,,,,,[],,,,
760902147303026689,760902147303026689,2016-08-03 23:46:23 IST,2016-08-03,23:46:23,+0530,1469603575,qtrresearch,Quoth the Raven,,SPLAT! Biogen Has Said Co. Has Not Received Any Formal Expressions of Interest from Suitors and is Not Soliciting Offers - Reuters $BIIB,en,[],[],[],4,1,6,[],['biib'],https://twitter.com/QTRResearch/status/760902147303026689,False,,0,,,,,,,,[],,,,
760820761749774336,760820761749774336,2016-08-03 18:22:59 IST,2016-08-03,18:22:59,+0530,54879118,biggercapital,Michael Bigger,,Interesting observation about Biogen's Poster for Promis Neurosciences  https://t.co/zIard9n59o $BIIB $PMN.TO $PMN.CA #endalz #Alzheimers,en,[],['http://www.newswire.ca/news-releases/promis-neurosciences-reports-highlights-from-the-2016-alzheimers-association-international-conference-589040391.html'],[],0,4,5,"['endalz', 'alzheimers']","['biib', 'pmn.to', 'pmn.ca']",https://twitter.com/biggercapital/status/760820761749774336,False,,0,,,,,,,,[],,,,
760587542349619204,760587542349619204,2016-08-03 02:56:15 IST,2016-08-03,02:56:15,+0530,1469603575,qtrresearch,Quoth the Raven,,SPLAT! BREAKING: Allergan unlikely to pursue Biogen deal - source (via @megtirrell) $AGN $BIIB,en,"[{'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}]",[],[],3,10,18,[],"['agn', 'biib']",https://twitter.com/QTRResearch/status/760587542349619204,False,,0,,,,,,,,[],,,,
760561107366842368,760561107366842368,2016-08-03 01:11:13 IST,2016-08-03,01:11:13,+0530,818081647,analystwire,SIAnalystWire,,Biogen $BIIB Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee  https://t.co/niHMKrcExi,en,[],['http://streetinsider.com/r/11892307'],[],1,4,5,[],['biib'],https://twitter.com/AnalystWire/status/760561107366842368,False,,0,,,,,,,,[],,,,
753978383734870016,753978383734870016,2016-07-15 21:13:49 IST,2016-07-15,21:13:49,+0530,61342056,optionshawk,Joe Kunkle,,"Biogen $BIIB opening buyers of 950 July 29th (W) $262.50 calls, captures 7-21 earnings, a name that could also be active in M&amp;A deals",en,[],[],[],0,6,11,[],['biib'],https://twitter.com/OptionsHawk/status/753978383734870016,False,,0,,,,,,,,[],,,,
745935708737544192,745935708737544192,2016-06-23 16:35:06 IST,2016-06-23,16:35:06,+0530,102754598,johncendpts,John Carroll,,Is Biogen the most desperate buyer scouting the #biotech market? $BIIB --   https://t.co/vaC3tCDlY0,en,[],['http://endpts.com/is-biogen-the-most-desperate-buyer-scouting-the-biotech-market/'],[],2,5,4,['biotech'],['biib'],https://twitter.com/JohnCendpts/status/745935708737544192,False,,0,,,,,,,,[],,,,
745722825550467072,745722825550467072,2016-06-23 02:29:11 IST,2016-06-23,02:29:11,+0530,102754598,johncendpts,John Carroll,,Is Biogen the most desperate buyer scouting the biotech market? $BIIB  https://t.co/vaC3tClL6s,en,[],['http://endpts.com/is-biogen-the-most-desperate-buyer-scouting-the-biotech-market/'],[],5,8,7,[],['biib'],https://twitter.com/JohnCendpts/status/745722825550467072,False,,0,,,,,,,,[],,,,
741025619211755520,741025619211755520,2016-06-10 03:24:09 IST,2016-06-10,03:24:09,+0530,85443769,formacionenmk,Raul Hernandez,,Will Major Setback Lead Biogen Inc (BIIB) to Bankruptcy?  https://t.co/bj11RJFWWS,en,[],['http://klou.tt/1qsnxjggzsrld'],[],0,4,4,[],[],https://twitter.com/formacionenmk/status/741025619211755520,False,,0,,,,,,,,[],,,,
712368906178985984,712368906178985984,2016-03-23 01:32:37 IST,2016-03-23,01:32:37,+0530,31546412,tradehawk,TradeHawk,,$BIIB Kyle Bass IPR INSTITUTED against challenged Biogen '514 Tefidera patent.  https://t.co/IEoPaobp03,et,[],['https://www.scribd.com/doc/305650384/IPR2015-01993-Instituted'],[],0,3,5,[],['biib'],https://twitter.com/TradeHawk/status/712368906178985984,False,,0,,,,,,,,[],,,,
710498132233166849,710498132233166849,2016-03-17 21:38:49 IST,2016-03-17,21:38:49,+0530,600378539,ralph_acampora,Ralph Acampora CMT,,Biogen (BIIB) is about to retest critical support at 242.07; if broken it will extend a downtrend that began at its March 2015 peak.,en,[],[],[],0,3,8,[],[],https://twitter.com/Ralph_Acampora/status/710498132233166849,False,,0,,,,,,,,[],,,,
697166238582231040,697166238582231040,2016-02-10 02:42:38 IST,2016-02-10,02:42:38,+0530,1287251676,megkesh,Meghana Keshavan,,"$BIIB Biogen CEO: Crush drug prices, and you crush drug R&amp;D #BIOCEO16  https://t.co/pBnd2fVqNN",en,[],['http://bit.ly/1SGxdhA'],[],0,8,7,['bioceo16'],['biib'],https://twitter.com/megkesh/status/697166238582231040,False,,0,,,,,,,,[],,,,
692325940383318017,692325940383318017,2016-01-27 18:09:01 IST,2016-01-27,18:09:01,+0530,61342056,optionshawk,Joe Kunkle,,"$BIIB - Biogen one of the lone bright spots int he reports this morning, indicated up 6%",en,[],[],[],1,1,7,[],['biib'],https://twitter.com/OptionsHawk/status/692325940383318017,False,,0,,,,,,,,[],,,,
684707973353095168,684707973353095168,2016-01-06 17:37:56 IST,2016-01-06,17:37:56,+0530,102754598,johncendpts,John Carroll,,Biogen backs Rodin's Alzheimer's efforts in a $500M deal $BIIB @DamianFierce   https://t.co/W0Noqss4Te,en,[],['http://www.fiercebiotech.com/story/biogen-backs-rodins-alzheimers-efforts-500m-deal/2016-01-06'],[],0,13,9,[],['biib'],https://twitter.com/JohnCendpts/status/684707973353095168,False,,0,,,,,,,,[],,,,
659528151102570496,659528151102570496,2015-10-29 06:02:19 IST,2015-10-29,06:02:19,+0530,26775476,hedgefundclone,hedgefundclone,,"Carl Icahn's Former Head of Healthcare Investing, Alex Denner of Sarissa Capital, just purchased almost $80 million of $BIIB @biogen",en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],[],0,1,10,[],['biib'],https://twitter.com/hedgefundclone/status/659528151102570496,False,,0,,,,,,,,[],,,,
656795924635721728,656795924635721728,2015-10-21 17:05:25 IST,2015-10-21,17:05:25,+0530,59393368,livesquawk,LiveSquawk,,"Biogen Inc Q3 15 results: Adj EPS came in at $4.48 (est $3.77); with Revenue of $2.8B (est $2.64B), To Cut 11% Of Jobs $BIIB",en,[],[],[],0,4,5,[],['biib'],https://twitter.com/LiveSquawk/status/656795924635721728,False,,0,,,,,,,,[],,,,
651737132931780611,651737132931780611,2015-10-07 18:03:35 IST,2015-10-07,18:03:35,+0530,386616537,tstbiotech,TheStreet Biotech,,Biogen Is Preparing for a 40% Rally in the Next 12 Months $BIIB  http://t.co/sRY09sjLKl  http://t.co/d2NpVNjSb9,en,[],['http://dlvr.it/CN99Lt'],['https://pbs.twimg.com/media/CQtvd_wUcAALnoQ.jpg'],0,7,5,[],['biib'],https://twitter.com/TSTbiotech/status/651737132931780611,False,,1,https://pbs.twimg.com/media/CQtvd_wUcAALnoQ.jpg,,,,,,,[],,,,
624559942343761920,624559942343761920,2015-07-24 18:11:08 IST,2015-07-24,18:11:08,+0530,42589787,newsquawk,Newsquawk,,US PRE-MARKET MOVERS:  Stancorp Financial $SFG +49.3% Amazon $AMZN +21.4% Starbuck $SBUX +4.4% Biogen $BIIB -11.7%  AbbVie $ABBV -3.4%,en,[],[],[],0,8,4,[],"['sfg', 'amzn', 'sbux', 'biib', 'abbv']",https://twitter.com/Newsquawk/status/624559942343761920,False,,0,,,,,,,,[],,,,
624374078493880320,624374078493880320,2015-07-24 05:52:35 IST,2015-07-24,05:52:35,+0530,466333756,seeitmarket,See It Market,,"New Post - ""Can Biogen Regain Its Mojo? BIIB Earnings On Tap...""  http://t.co/bzMFvZNPcI by @atmcharts $BIIB $IBB  http://t.co/zrsvA13J34",et,"[{'screen_name': 'atmcharts', 'name': 'atmcharts', 'id': '255249826'}]",['http://www.seeitmarket.com/can-biogen-regain-its-mojo-biib-earnings-on-tap-14594/'],['https://pbs.twimg.com/media/CKo46j5VAAAb7Zt.jpg'],1,4,5,[],"['biib', 'ibb']",https://twitter.com/seeitmarket/status/624374078493880320,False,,1,https://pbs.twimg.com/media/CKo46j5VAAAb7Zt.jpg,,,,,,,[],,,,
623806416881479685,623806416881479685,2015-07-22 16:16:54 IST,2015-07-22,16:16:54,+0530,102754598,johncendpts,John Carroll,,"In a setback, Biogen's mid-range dose of aducanumab flops in Alzheimer's study $BIIB  http://t.co/wIAaI1J7lf",en,[],['http://www.fiercebiotech.com/story/setback-biogens-mid-range-dose-aducanumab-flops-alzheimers-study/2015-07-22'],[],0,20,10,[],['biib'],https://twitter.com/JohnCendpts/status/623806416881479685,False,,0,,,,,,,,[],,,,
623140187216986112,623140187216986112,2015-07-20 20:09:32 IST,2015-07-20,20:09:32,+0530,13171622,pharmalot,pharmalot,,Will test results for Lilly and Biogen Alzheimer's drug be hard to forget?   http://t.co/YvByeRXUV3 #pharma $LLY $BIIB #Alzheimers,en,[],['http://blogs.wsj.com/pharmalot/2015/07/20/will-trial-results-for-lilly-and-biogen-alzheimers-drugs-be-hard-to-forget/'],[],0,4,7,"['pharma', 'alzheimers']","['lly', 'biib']",https://twitter.com/pharmalot/status/623140187216986112,False,,0,,,,,,,,[],,,,
619659566934962177,619659566934962177,2015-07-11 05:38:48 IST,2015-07-11,05:38:48,+0530,2290157628,thepbr1000,The PBR1000,,"#Biogen(PBR358) R&amp;D leader Doug Williams, PhD, leaving to be CEO of a startup, new R&amp;D co-leaders named.  http://t.co/Q1XHP9qRSu $BIIB",en,[],['http://bit.ly/1Gd249j'],[],0,0,6,['biogen'],['biib'],https://twitter.com/ThePBR1000/status/619659566934962177,False,,0,,,,,,,,[],,,,
616337868709990400,616337868709990400,2015-07-02 01:39:33 IST,2015-07-02,01:39:33,+0530,100024370,ophirgottlieb,Ophir Gottlieb,,Why Biogen ( $BIIB ) Is Inches Away From Changing the World and $500 in Stock Price  http://t.co/6knKQbTmDY  http://t.co/onedZXyktS,en,[],['http://tmblr.co/ZlozNl1nZsdVS'],['https://pbs.twimg.com/media/CI2sBhYVAAAG94g.png'],1,4,7,[],['biib'],https://twitter.com/OphirGottlieb/status/616337868709990400,False,,1,https://pbs.twimg.com/media/CI2sBhYVAAAG94g.png,,,,,,,[],,,,
596669951227727872,596669951227727872,2015-05-08 19:06:16 IST,2015-05-08,19:06:16,+0530,18639734,nasdaq,Nasdaq,,.@Biogen takes over #TimesSquare after the @Nasdaq Opening Bell! #BiogenOpeningBell $BIIB  http://t.co/nHqUgZjIK2,en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'nasdaq', 'name': 'nasdaq', 'id': '18639734'}]",[],['https://pbs.twimg.com/media/CEfMJ4eWEAAXQmz.jpg'],2,20,16,"['timessquare', 'biogenopeningbell']",['biib'],https://twitter.com/Nasdaq/status/596669951227727872,False,,1,https://pbs.twimg.com/media/CEfMJ4eWEAAXQmz.jpg,,,,,,,[],,,,
596668395749298177,596668395749298177,2015-05-08 19:00:05 IST,2015-05-08,19:00:05,+0530,18639734,nasdaq,Nasdaq,,.@Biogen rings the @Nasdaq Opening Bell! #BiogenOpeningBell $BIIB #N100  http://t.co/WymnEbAXZR,en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'nasdaq', 'name': 'nasdaq', 'id': '18639734'}]",[],"['https://pbs.twimg.com/media/CEfKu_-UEAAhLG5.jpg', 'https://pbs.twimg.com/media/CEfKvNDUMAEhrVh.jpg', 'https://pbs.twimg.com/media/CEfKvanUkAEPqRv.jpg', 'https://pbs.twimg.com/media/CEfKvovUUAAOiMg.jpg']",1,12,9,"['biogenopeningbell', 'n100']",['biib'],https://twitter.com/Nasdaq/status/596668395749298177,False,,1,https://pbs.twimg.com/media/CEfKu_-UEAAhLG5.jpg,,,,,,,[],,,,
596663172074901504,596663172074901504,2015-05-08 18:39:20 IST,2015-05-08,18:39:20,+0530,18639734,nasdaq,Nasdaq,,Exciting morning with @Biogen here to ring the @Nasdaq Opening Bell! #BiogenOpeningBell $BIIB #N100  http://t.co/zhiyq6zORW,en,"[{'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'nasdaq', 'name': 'nasdaq', 'id': '18639734'}]",[],"['https://pbs.twimg.com/media/CEfF-r-UEAMS7We.jpg', 'https://pbs.twimg.com/media/CEfF-siVEAAh2cR.jpg', 'https://pbs.twimg.com/media/CEfF-slUMAAtOFL.jpg', 'https://pbs.twimg.com/media/CEfF-sCVEAMflav.jpg']",1,16,13,"['biogenopeningbell', 'n100']",['biib'],https://twitter.com/Nasdaq/status/596663172074901504,False,,1,https://pbs.twimg.com/media/CEfF-r-UEAMS7We.jpg,,,,,,,[],,,,
587794809416523776,587794809416523776,2015-04-14 07:19:37 IST,2015-04-14,07:19:37,+0530,51932290,lin_ling_88,Helen Ong,,Should Biogen Be Afraid of This Upstart? $BIIB $RCPT  http://t.co/1y8nViX02f,en,[],['http://www.investopedia.com/stock-analysis/041315/should-biogen-be-afraid-upstart-biib-rcpt.aspx'],[],2,3,4,[],"['biib', 'rcpt']",https://twitter.com/Lin_ling_88/status/587794809416523776,False,,0,,,,,,,,[],,,,
585284657966686209,585284657966686209,2015-04-07 09:05:11 IST,2015-04-07,09:05:11,+0530,21328656,ibdinvestors,Investors.com,,"How to Buy on a Pullback: After getting support at 10-week line, is time to buy Biogen?  http://t.co/EpRQ1Ayfke $BIIB",en,[],['http://ibdn.uz/LgFvf'],[],0,6,12,[],['biib'],https://twitter.com/IBDinvestors/status/585284657966686209,False,,0,,,,,,,,[],,,,
579962787784458240,579962787784458240,2015-03-23 16:37:58 IST,2015-03-23,16:37:58,+0530,44438256,matthewherper,Matthew Herper,,"$BIIB drops the ""Idec"", becoming just Biogen, and making headline-writing easier.  http://t.co/nqZhr6urhZ",en,[],['http://finance.yahoo.com/news/biogen-idec-becomes-biogen-100000618.html'],[],1,5,7,[],['biib'],https://twitter.com/matthewherper/status/579962787784458240,False,,0,,,,,,,,[],,,,
578881029974454272,578881029974454272,2015-03-20 16:59:27 IST,2015-03-20,16:59:27,+0530,61342056,optionshawk,Joe Kunkle,,Coach Hunter reacting to the Biogen $BIIB Alzheimer's Data  https://t.co/kiKwKG6L7n,en,[],['https://vine.co/v/OYu99BxFHJ0'],[],1,4,13,[],['biib'],https://twitter.com/OptionsHawk/status/578881029974454272,False,,0,,,,,,,,[],,,,
578874897658556416,578874897658556416,2015-03-20 16:35:05 IST,2015-03-20,16:35:05,+0530,386616537,tstbiotech,TheStreet Biotech,,"Biogen's Alzheimer's Drug Exceeds (or Meets) Expectations, Depending on Your View $BIIB  http://t.co/DYdQcCmHtu  http://t.co/JQ7D3YCdR2",en,[],['http://dlvr.it/92kNGJ'],['https://pbs.twimg.com/media/CAiTpvuU0AAI_WN.jpg'],1,11,10,[],['biib'],https://twitter.com/TSTbiotech/status/578874897658556416,False,,1,https://pbs.twimg.com/media/CAiTpvuU0AAI_WN.jpg,,,,,,,[],,,,
578871289466748928,578871289466748928,2015-03-20 16:20:44 IST,2015-03-20,16:20:44,+0530,44438256,matthewherper,Matthew Herper,,"Biogen Drug Could Inspire New Hope For Alzheimer's Treatments  http://t.co/0Xwmz0jDMg &lt;-- also statistical issues, side effects. $BIIB",en,[],['http://onforb.es/1994j4v'],[],3,23,9,[],['biib'],https://twitter.com/matthewherper/status/578871289466748928,False,,0,,,,,,,,[],,,,
563138778811088896,441200778188161024,2015-02-05 06:25:22 IST,2015-02-05,06:25:22,+0530,632341632,andybiotech,Andy Biotech,,$BIIB - Eisai discloses details of its options of #Alzheimer‚Äôs deal w/ Biogen  http://t.co/qSHxoOPAjx HT @DionCapital  http://t.co/K4xDNERlKc,en,[],['http://www.eisai.com/news/enews201507pdf.pdf'],['https://pbs.twimg.com/media/B8mnzUaIcAAoG3s.png'],3,5,10,['alzheimer'],['biib'],https://twitter.com/AndyBiotech/status/563138778811088896,False,,1,https://pbs.twimg.com/media/B8mnzUaIcAAoG3s.png,,,,,,,[],,,,
539886698176716801,539886698176716801,2014-12-03 02:29:54 IST,2014-12-03,02:29:54,+0530,466185506,m_cof,Michelle Coffey,,Biogen up sharply after Alzheimer's drug gets fast-tracked to Phase 3 testing  http://t.co/sEF8BNLxEV $BIIB  http://t.co/ZsvvHqigR9,en,[],['http://on.mktw.net/12ocB5W'],['https://pbs.twimg.com/media/B34PkjQCUAAQU0A.png'],2,10,7,[],['biib'],https://twitter.com/m_cof/status/539886698176716801,False,,1,https://pbs.twimg.com/media/B34PkjQCUAAQU0A.png,,,,,,,[],,,,
